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ABSTRACT
  AIMS AND OBJECTIVES
1. To estimate Sr.Zinc levels at detection of Type 2 Diabetes
mellitus.
2. To study the effect of Zinc supplementation on glycemic
Control as evaluated by HbA1C in newly detected type 2 diabetic
patients.
Secondary Objectives:
   1. To study the effect of supplementation of Zinc on Lipid  profile, &
          Body Mass Index in newly detected type 2 diabetic patients.
INCLUSION CRITERIA
1. Newly diagnosed Type 2 diabetic subjects without complications,
attending ESIC PGIMSR MEDICAL OPD ,KK Nagar,Chennai-78.
2. Age ? 20.
3. Gender – both male and female.
EXCLUSION CRITERIA
1. Type-1 Diabetes,
2. Type-2 diabetics with complications
3. Diabetes in pregnancy
4. Chronic kidney disease
5.  Chronic Liver Disease, Chronic Pancreatitis or IBD (Inflammatory
Bowel disease)
6. Subjects on Zinc supplementation, Immunomodulators drugs,
chelating drugs.
CONSENT
All patients were recruited in the study after getting consent in the
consent form in vernacular language. Consent form was approved by
Institutional Ethical Committee, ESI PGIMSR, KK Nagar.
METHODS
All the new patients attending the OPD with risk factors for DM  or the
patients referred from ESI Dispensary  after urine glucose was positive or from
other departments were initially selected and after getting consent regarding
investigations and further inclusion in the study, patients were subjected to FBG
and HBA1C. After exclusion of patients with IFG or IGT or with normal
glucose  levels, remaining patients of about 140 patients were subjected to Ultra
sonogram abdomen to rule out chronic kidney disease, chronic liver disease,
fundus examination to rule out Diabetic Retinopathy and ECG, Blood Urea
Sr.Creatinine, Urine routine examination along with early morning urine
microalbuminuria were done. After completing investigations 140 patients
were divided randomly into two groups according to computer generated
random number. So each group consisted 70 patients .  Patient groups are
assigned as 1 and 2.
RESULTS
140 patients were included after meeting eligibility criteria in the study in
two groups and followed for a period of about one year . BMI, FBG, PPBG,
HBA1C, Serum Zinc Levels, Haemogram, Urine Routine analysis and
microalbuminuria were done and tabulated in the worksheet and analyzed.
Results are as follows:
Treatment Groups
Treatment
Groups
Name of
Group Treatment
Number of
Subjects
Group 1 Placebo
Placebo supplementation +
OHA  in newly detected type 2
diabetic patients
70
Group 2 Zinc
Zinc supplementation (50
mg/day) + OHA  in newly
detected type 2 diabetic
patients
70
In our study Mean age of the subjects was included with placebo group is
48.17 and Zinc group is 47.27. There is no significance between the groups
implying that there is about equal distribution in the Groups. Lowest age in the
study is 29 years and highest age 67 years. Maximum number of patients were
between the 41-50 years. There was about equal distribution of the male and
female patient about 1:1 ratio totally and in all groups. Serum Zinc levels in
most of the subjects in both groups were below 75 microgm/dl before Zinc
supplementation. After Zinc supplementation Serum Zinc levels were
significantly increased .  Statiscally this indicates that there is a true difference
within the Zinc supplementation group (pre and Post intervention) in relation to
HBA1c levels and the difference is significant.
             In simple terms, with Zinc supplementation in newly detected type 2
diabetic patients, the fasting blood glucose levels is reduced by 22 mg/dl in
comparison with placebo which reduces fasting blood sugar levels by 9.57
mg/dl with a p-value of 0.00079 according to unpaired t-test.
            In simple terms, with Zinc supplementation in newly detected type 2
diabetic patients, the post prandial  blood glucose levels is reduced by 45 mg/dl
in comparison with placebo which reduces post  prandial  blood sugar levels  by
16 mg/dl with a p-value of 0.0323 according to unpaired t-test.
Zinc supplementation in newly detected type 2 diabetic patients, the
HBA1c levels is reduced by 0.95% in comparison with placebo which reduces
HBA1c levels by 0.25% with a p-value of 0.00036 according to unpaired t-test.
The reduction in HBA1c levels was meaningfully more (79%) in the Zinc
supplementation group compared to the placebo group by 0.097 %.
      The difference within the treatment groups (pre and Post intervention)
and serum VLDL, TG, CHL, HDL, LDL levels is considered to be not
statistically significant since p > 0.05.
               BMI has not changed significantly after supplementation of Zinc
(p=0.186). BMI in pre interventional and post interventional groups was 27.97
and 26.99 respectively.
CONCLUSION
Zinc supplementation improves glycemic parameters HbA1C, FBG,
PPBG in newly detected Type 2 Diabetics when compared to placebo group.
Zinc supplementation with oral hypoglycemic agents may provide better
glycemic control. There is no significant effect on fasting lipid profile after Zinc
supplementation.
           Keywords :  Diabetes mellitus, Zinc, hypoglycaemic agents.
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INTRODUCTION
Diabetes mellitus (DM) refers to a group of metabolic disorders
which is characterized by  hyperglycemia. Ebers Papyrus, which was
written around 1500  before christ, excavated in 1862 AD from an ancient
grave in Thebes, (Egypt)  and published by Egyptologist Georg Ebers in
1874, describes, among various other ailments and their remedies, a
condition of “too nice emptying of the urine” – perhaps, the reference to
DM. For the treatment of this condition, ancient Egyptian physicians
were advocating the use of wheat grains, fruit. (1,2) It is one of the diseases
described since ancient period in Egypt. At the equivalent time
Physicians in Republic of India classified the disease as a separate entity
and termed it as Madhumeha or honey urine. (3) During Roman empire
DM was considered as rare illness. It was initially seen in upper
socioeconomic people due to their life style and food habits. Galen
referred the illness as diarrhea urinosa  "diarrhea of the urine". Around
230 BC, Apollonius of Memphis for the first time used the term
“diabetes,” which in Greek means “to pass through” (dia – through, betes
– to go). (3) The first complete clinical description of diabetes appears to
have been made by Aulus Cornelius Celsus (30BC–50 AD). (4,5)In 2nd or
early 3rd century AD Aretaeus of  Cappadocia wrote a book on DM that
forms the earliest reference. He described the symptoms of the illness and
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its natural course. The first Latin edition was released in Venice after
which his work came in light.
Type 1 and Type 2 diabetes were identified as distinct conditions
first time by the Indian physicians Sushruta and Charaka in 400-500 AD .
Rhey represented Type 1DM associated with youth and Type 2 DM with
being overweight. In 1670, Thomas Willis in Oxford noticed the sweet
taste of urine of patients with diabetes. Thomas Cawley, in 1788, was the
first to suggest the link between the pancreas and diabetes after he
observed that people with pancreatic injury developed diabetes.( 6 )In end
of 1700 AD the term "mellitus" or "from honey" was added  to Diabetes
to differentiate from Diabetes Insipidus by the Briton John Rolle.
It was Banting and Best who created  milestone in the history of
DM by isolating and purifying Insulin which is effective in managing the
cases of DM. They won the noble prize for their most useful discovery.
Then the long acting insulin was developed in 1940. Over the years,
insulin purification methods improved and new insulin formulations were
developed.
Protamine–Zinc insulin, a long-acting insulin, was introduced in
the 1930s; Neutral Protamine Hagedorn insulin(NPH) was introduced in
the 1940s; and Lente series of insulin in the 1950s.(7) The groundwork for
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the production of large quantities of human insulin was laid by Frederick
Sanger, who published  the structural formula of bovine insulin in 1955.(8)
Dorothy Hodgkin (1910–1994) described the three-dimensional structure
of porcine insulin in 1969 using X-ray crystallography.(9) The gene
coding for human insulin was cloned in 1978 by Genentech. It is located
on the short arm of chromosome 11. Once incorporated into the bacterial
plasmid of E. coli,  human insulin gene gets active, resulting in the
production of alpha and beta chains of insulin, which were then combined
to construct a complete insulin molecule.(10) In 1978, Genentech, Inc. and
City of Hope National Medical Center, a private research institution in
Duarte, California, announced the successful laboratory production of
human insulin using recombinant DNA technology. This was achieved by
a team of scientists led by Robert Crea, Keichi Itakura, David Goeddel,
Dennis Kleid and Arthur Riggs. Insulin thus became the first genetically
manufactured drug to be approved by the FDA. In July 1996, the FDA
approved the first recombinant DNA human insulin analog, the insulin
lispro. In January 2006, FDA approved inhaled form of insulin marketed
under the name of Exubera. This was the first non injectable form of
insulin available to patients with diabetes.
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Ninety percent of those with diabetes have type-2 diabetes,
characterized by insulin resistance, hyper insulinemia, ?-cell dysfunction
and subsequent ?–cell failure. Insulin, is stored as a hexamer containing
two Zinc ions in ?-cells of the pancreas and released into the portal
venous system at the time of ?-cells de-granulation. The Zinc  ions which
are co secreted with insulin suppress inherent amyloidogenic properties
of monomeric insulin. Zinc plays a key role in the synthesis and action of
insulin, both physiologically and in the pathologic state of diabetes.
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AIMS AND OBJECTIVES
1. To estimate Sr.Zinc levels at detection of Type 2 Diabetes
mellitus.
2. To  study  the  effect  of  Zinc supplementation on glycemic
Control as evaluated by HbA1C in newly detected
type 2 diabetic  patients.
Secondary Objectives:
1.  To  study  the  effect  of  supplementation  of  Zinc  on  Lipid   profile,
& Body Mass Index in newly detected type 2 diabetic patients.
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REVIEW OF LITERATURE
DM is a group of metabolic disorders characterized by chronic
hyperglycemia. Few forms of DM are characterized in terms of their
specific pathogenesis, but the underlying etiology of the most common
forms remains unclear. Regardless of the etiology, diabetes progresses
through several clinical stages during its natural history. Persons
developing the disease can be categorized according to clinical stages and
other characteristics even in the absence of knowledge of the etiology. In
development of  DM there are multiple interaction  between  genetic  and
environmental factors. There are so many factors that contribute to
development of hyperglycemia such as reduced insulin secretion,
decreased glucose utilization, insulin resistance, increased glucose
production, increased  anti insulin hormone production.
DM is characterized by chronic hyperglycemia with disturbances
of carbohydrate, fat, and protein metabolism resulting from defects in
secretion of insulin, its action, or both. When fully expressed, diabetes is
characterized by fasting hyperglycemia, but the disease can also be
recognized during less overt stages, usually by the presence of glucose
intolerance. The effects of DM include long-term damage, dysfunction,
and failure of multiple organs, especially the eyes, kidneys, heart, and
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blood vessels. Diabetes may present with characteristic symptoms such as
polydipsia, polyuria, polyphagia, blurring of vision and weight loss, in its
most severe forms, with ketoacidosis or non ketotic hyperosmolarity,
which, in the absence of effective treatment, leads to stupor, coma, and
death. Often symptoms are not severe or may even be absent.
Hyperglycemia sufficient to cause pathologic functional changes may
quite often be present for a long time before the diagnosis is made.
Consequently, diabetes often is discovered because of abnormal results
from a routine blood or urine glucose test or because of the presence of a
complication. In some instances diabetes may be apparent only
intermittently, as, for example, with glucose intolerance in pregnancy or
gestational diabetes, which may remit after parturition. In some
individuals the likelihood of developing diabetes may be recognized even
before any abnormalities of glucose tolerance are apparent. During the
evolution of type 1 diabetes, for example, immunologic disturbances such
as islet cell or other antibodies are present, and these may precede
clinically apparent disease by months or even years .  In some families it
is possible to recognize certain gene mutations that are strongly
associated with certain forms of diabetes, such as variations in the
glucokinase gene or hepatic nuclear factor genes that cause young or
early adult-onset diabetes.  These genetic abnormalities are detectable at
19
any time. Now DM classification is based on pathogenic process that
leads to hyperglycemia. DM is classified into Type 1 and Type 2.
Whatever the type of  diabetes, a period of abnormal glucose metabolism
occurs before full blown disease is diagnosed. Near total deficiency or
complete  deficiency  of  insulin  leads  to   Type  1  DM.  Type  2  DM  can
result from variety of causes such as a.) insulin resistance, b.) impaired
insulin secretion, and c.) increased glucose  production. In Type 2 DM
unique genetic, metabolic defects in insulin action or its secretion leads to
development of hyperglycemia. Targeting this we have specific
pharmacologic agents now. Type 2 DM is preceded by impaired fasting
glucose (IFG) or impaired glucose tolerance (IGT). Type-1 DM is an
autoimmune disorder and Type-2 DM is a metabolic  cum vascular
disease.
20
FIG.3.1 :  CLASSIFICATION OF DM
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EPIDEMIOLOGY
Globally, as of 2010, an estimated 285 million people had diabetes,
with type 2 making up about 90% of the cases.(11) In 2013, according to
International Diabetes Federation, an estimated 381 million people had
diabetes. Its prevalence is increasing rapidly, and by 2030, this number is
estimated to almost double.(13) DM occurs throughout the world, but is
more common (especially type 2) in the more developed countries. The
greatest increase in prevalence is, however, expected to occur in Asia and
Africa, where most patients will probably be found by 2030. The increase
in incidence in developing countries follows the trend of urbanization and
lifestyle changes, perhaps most importantly a "Western-style" diet. This
has suggested an environmental (i.e., dietary) effect, but there is little
understanding of the mechanism(s) at present, though there is much
speculation, some of it most compellingly presented.(13) India has more
diabetics than any other country in the world, according to the
International Diabetes Foundation(15) although more recent data suggest
that China has even more.(14) The disease affects more than 62 million
Indians, which is more than 7.1% of India's Adult Population.(16) An
estimate shows that nearly 1 million Indians die due to Diabetes every
year.(15) The average age of onset is 42.5 years.(15) The high incidence is
attributed to a combination of genetic susceptibility plus adoption of a
high-calorie diet, low-activity lifestyle by India's growing middle
class.(17) Additionally, a study by the American Diabetes Association
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reports that India will see the greatest increase in people diagnosed with
diabetes by 2030.(18)
In India, prevalence of  DM is about 9.1% in 2013 and expected to
rise to 9.7% in 2035. In 2013 number of persons with DM is 65,076,400
and this is expected to rise 109,028,100 in a tough competition for the
DIABETIC CAPITAL OF WORLD with China. Number of  undiagnosed
DM cases in India is estimated to be about 31,920,000 in 2013. In India
in 2013 number of deaths attributed to DM is estimated to be around
1,065,053. In South India ,Type-2 DM has a prevalence rate >10% .
FIGURE 3.2: PREVALANCE OF DIABETES
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DIAGNOSIS of Type 2 Diabetes is According to American
Diabetic Association guidelines as listed below
TABLE 3.1: CRITERIA FOR  DIAGNOSIS OF DM :
1) Symptoms of diabetes plus random blood glucose
concentration > 11.1 mmol/L (200 mg/dL)a or
2) Fasting plasma glucose > 7.0 mmol/L (126 mg/dL)b or
3) A1C > 6.5%c or
4) Two-hour plasma glucose > 11.1 mmol/L (200mg/dL)
during an oral glucose tolerance testd
Abnormal glucose homeostasis is
A. FPG -100 -125mg/dl -IFG-Impaired Fasting Glucose
B. Plasma glucose levels after 2 hours following an oral glucose
challenge--140 and 199 mg/dl, termed as impaired glucose
tolerance (IGT); or
C. HBA1C of 5.7–6.4%.
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WHO criteria for the diagnosis of diabetes (27)
1)  Symptoms of diabetes plus casual venous plasma glucose-11.1 m
mol/l. Casual is defined as any time of day without regard to time
since last meal. The classic symptoms of diabetes include polyuria,
polydipsia, and unexplained weight loss.
2)  Fasting plasma glucose -7.0 m mol/l or whole blood-6.1 m mol/l.
Fasting is defined as no calorie intake for at least 8 hours
3) 2 hour plasma glucose -11.1 m mol/l during oral glucose tolerance
test  using 75 g glucose load.
In the absence of symptoms, these criteria should be confirmed by
repeat testing on a different day. If the fasting or random values are not
diagnostic, the 2 hour value post-glucose load should be used.
Note:
Fasting plasma glucose -6.1 m mol/l—normal
Fasting plasma glucose -6.1 to 7.0 m mol/l—impaired fasting
blood glucose
Fasting plasma glucose -7.0 m mol/l—provisional diagnosis of
diabetes; the diagnosis must be confirmed.
         The current diagnostic criteria DM relies mainly on A1C or the FPG
as they are reliable and convenient parameters . This is also used in
asymptomatic individuals.
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SCREENING
Every 3 years, Screening of individuals >45 years and the people
whose body mass index (BMI) >25 kg/m2 at  an  earlier  age  and  having
any of additional risk factor for diabetes listed below is essential because,
1. Asymptomatic condition and lack of awareness
2. Early start of the disease before diagnosis
3. At the time of diagnosis patient may have complications related to
disease
4. Early treatment prevents complications and delays its progression .
TABLE - 3.2: RISK FACTORS-FOR DEVELOPMENT OF TYPE 2
DM
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ZINC DEFICIENCY :
Zinc deficiency is more common in developing countries(19), where
diabetes is also showing an exponential increase in prevalence. The
prevalence of CAD, diabetes and glucose intolerance was significantly
higher among subjects consuming lower intakes of dietary Zinc. There
was a higher prevalence of hypertension, hypertriglyceridemia and low
high-density lipoprotein cholesterol levels which showed significant
upward trend with lower Zinc intakes.
Animal studies have shown that Zinc supplementation improves
fasting insulin level and fasting glucose in mice.(19) Human studies have
also shown the beneficial effects of Zinc supplementation in both type-
1(20,21) and type-2 diabetes.(22,23) However, results of isolated randomized
controlled trials are frequently contradicted by subsequent studies.(24)
Especially, in type-1 diabetes studies have reported a negative effect of
Zinc supplementation on glucose homeostasis.(25) Even under the most
rigorous study design conditions, even a well-planned single study, rarely
provides definitive results and changing clinical practices relying on a
single high-profile clinical trial can be harmful to patients health . Well-
designed randomized controlled trials are excellent when looking at
effectiveness, though many fall short in reporting of safety and adverse
events associated with an intervention. Systematic reviews often have
increased power and decreased bias as compared with the individual
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studies they include, and the careful pooling of treatment effects can
provide the most accurate overall assessment of an intervention.
Presently there are no systematic reviews exploring the therapeutic
efficacy of Zinc supplementation in humans with diabetes. This study
aims to systematically evaluate the literature and the effects of Zinc
supplementation in humans.
ZINC – AN ESSENTIAL ELEMENT
Zinc is an essential trace element that is important in many
biological processes and cellular homeostasis. Disturbed Zinc signaling
process is associated with variety of chronic disease states including
cancer, cardio vascular disease and diabetes. For maintaining cellular
homeostasis and insulin synthesis Zinc is essential. Zinc, an essential
mineral that is naturally present in some foods, added to others, and  also
available as a dietary supplement. Zinc is involved in various cellular
metabolisms.
It  is  also  required  for  the  action  of   many  enzymes  and  it  plays  a
role in immune function(28),protein synthesis, wound healing, cell division
and DNA synthesis. It also supports normal growth and development
during pregnancy, childhood, it is also required for proper sense of smell
and taste.
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So a steady daily intake of Zinc is required to because the body has
no specialized Zinc storage system.
Zinc is an important component of most of the enzymes like
Carbonic anhydrase, peptidase, Alcohol dehydrogenase, Alkaline
phosphatase, Polymerase, Superoxide dismutase, Angiotensin converting
enzyme, Collagenase, Amino levulinic acid, Protein Kinase C,
Phospholipase, RNAse etc.
Recommended dietary allowances (RDA)
Average daily level of intake sufficient to meet the nutrient
requirements of nearly all healthy individuals. The current RDAs for Zinc
are listed in table 3.
TABLE 3.3: RECOMMENDED DIETARY ALLOWANCES(RDAS)
FOR ZINC (30)
Age
0-6 months
<3 years
4-8 years
9-13 years
14-18 years
19+
Male
2mg
3mg
5mg
8mg
11mg
11mg
Female
2mg
3mg
5mg
8mg
9mg
8mg
Pregnancy
12mg
11mg
Lactation
13mg
12mg
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Tolerable upper intake intake level (UL) : (30)
Prolonged intake above the upper limit increases the risk of
adverse health effects. (30)Importantly these upper limits are not applicable
for those who are receiving Zinc for medical treatment, but such
individuals should be under the care of a physician who monitors them
for adverse effects.
TABLE 3.4:  TOLERABLE UPPER INTAKE LEVELS FOR
ZINC(30)
Age
0-6 months
7-12months
1-3 years
4-8 years
9-13 years
14-18 years
19+ years
Male
4mg
5mg
7mg
12mg
23mg
34mg
40mg
Female
4mg
5mg
7mg
12mg
23mg
34mg
40mg
Pregnant
34mg
40mg
Lactating
34mg
40mg
Major Causes of Zinc Deficiency : (29)
A. Inadequate intake :
1)  Low-Zinc-containing diets:
    Vegetarians ( foods poor in animal origin )
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2) Loss of Zinc during food processing : ( desalting during production
of artificial milk)
3) Prolonged enteral nutrition
B. Malabsorption
1) Congenital : Acrodermatitis enteropathica
2) Acquired:
a) Ingestion of absorption inhibitors -  phytic acid, fibers
b) Malabsorption syndromes – Liver dysfunction, Pancreatic
dysfunction, Inflammatory Bowel disease etc
c) Chelating agents: EDTA, Pencillamine
C.  Increased elimination :
a) Loss into digestive fluids – chronic diarrhea, intestinal
fistula
b) Enhanced urinary elimination – Diabetes, Kidney disease,
Hemolytic anemias, Diuretics
c) Others : Surgery, Infections, Trauma, Burns
D.  Enhanced demand :
a) Pregnancy, Premature babies
b) Enhanced anabolism
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TABLE 3.5: POSSIBLE CONDITIONS SUGGESTED BY SERUM
ZINC LEVELS AND ITS IMPLICATIONS(29)
SERUM  ZINC
LEVELS
(MICROGM/DL)
CONDITIONS IMPLICATIONS
84-159
60-83
<59
<30
>160
Normal Range
Mild deficiency
Moderate deficiency
Severe deficiency
Intoxication
Identification of cause
Zinc replacement
Identification of cause
Zinc replacement
Identification of cause
Zinc replacement
First aid and follow up
Uses of Zinc : (31)
Diarrhea in malnourished children 10-40 mg elemental Zinc daily for 14
days  in   Acute Watery Diarrhoea as
per the requirement of IMNCI
guidelines of  government of India.
Attention defecit hyperactivity 55 mg Zinc sulphate (15 mg
elemental  Zinc) to 150 mg (40 mg
elemental   Zinc)  daily.
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Osteoporosis 15mg  Zinc combined with 5 mg
manganese, 1000 mg calcium, and
2.5 mg copper has been used.
Treatment of pneumonia 10-70 mg/day
Hypogeusia 25-100 mg/day
(a sense of abnormal taste)
Anorexia nervosa 100 mg of Zinc gluconate daily
Gastric ulcers Zinc sulphate 200 mg three times
                                                              daily.
Muscle cramps in  liver diseases    Zinc sulphate 220 mg twice daily.
Sickle cell disease                           Zinc sulphate 220 mg three times
                                                              daily.
To increase growth and weight gain
in children with sickle cell disease       Zinc 10 mg (elemental) per day.
who have not reached puberty
Acne vulgaris 30-135 mg elemental Zinc daily.
Age related macular degeneration:    Elemental Zinc 80 mg plus vitamin
C 500 mg, vitamin E and vitamin
A 15  mg daily.
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Common cold:
One Zinc gluconate or acetate lozenge, providing 9-24 mg
elemental Zinc, can be taken by mouth every two hours while awake
when cold symptoms are present.
Different salt forms:
Zinc sulphate contains 23% elemental Zinc ; 220 mg of Zinc
sulphate contains 50 mg elemental Zinc. Regards Zinc gluconate it
contains 14.3% elemental Zinc; 10 mg Zinc gluconate contains 1.43 mg
Zinc.
Toxicity :
Zinc toxicity can occur in two types:
           1) Acute form
           2) Chronic form
1) Acute form:
Acute adverse effects of high Zinc intake include the following
nausea, vomiting, abdominal cramps, diarrhea, and headaches and loss of
appetite (2). One study showed that severe nausea and vomiting within 30
minutes of ingesting 4 gram of Zinc gluconate (570 mg elemental
Zinc).(32)
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2) Chronic form:
            Intake of 150-450 mg of Zinc per day have been associated with
chronic effects like low copper status, affecting iron metabolism, reduced
immune function, and reduced levels of high density lipoproteins. (33)
Afkhami-Ardekani et al., reported that patients receiving Zinc
sulphate 660 mg /day for 12 weeks had mild abdominal pain (19).
Patients who received Zinc sulphate (22 mg /day) and Zinc acetate (50
mg /day) for a period of 34 months showed that no significant adverse
effects on renal and liver function tests.(33)
Diabetes and Zinc
DM type 2 is charecterised by hyperinsulinemia, dysfunction of
beta cells and cellular failure.(34) Insulin is stored as a hexamer containing
2 Zinc ions in cells of pancreas and released into the portal circulation at
the time of beta cell degranulation.(35) The  Zinc  (II)  ions  which  are  co-
secreted with insulin suppress the inherent amyloidogenic properties of
monomeric insulin.(36) Zalewski et al showed that high concentration of
glucose and other secretogogues decrease the islet cell labile Zinc and
video fluroscence analysis showed Zinc concentration in the islet cells
was related to the synthesis, storage and secretion of insulin.(37) In vitro
data suggests that insulin binds to isolated liver membranes to a greater
extent and that there is less degradation when co-aDMinistered with
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Zinc.(38) Zinc is important in insulin action and carbohydrate
metabolism.(39) Oxidative stress is important in development of diabetes
and its vascular complication. Zinc is also a part of anti oxidant enzymes
like superoxide dismutase and its deficiency leads to oxidative stress.
Studies have shown that diabetes is charecterised by hypoZincemia (40)
and hyperZincuria.(41) In addition Zinc deficiency is more common in
men of developing countries (42) where diabetes is more common. Animal
studies have shown that Zinc supplementation improves fasting insulin
level and decreases fasting glucose in mice.(43) Human studies have
shown that the beneficial effects of Zinc supplementation in both
type1(44,45) and type 2DM .(46,47)
The cellular homeostasis is particularly achieved through the
actions of  Zinc transporters and metalothioneins. In diabetes the role of
Zinc is emerging now. Zinc is very important in the synthesis ,  storage
and secretion of insulin in both physiological and patho physiological
states. It also plays a dynamic role as a cellular second messenger in the
control of insulin signaling and glucose metabolism. This suggests that
Zinc plays an unidentified role as a second messenger that augments
insulin activity and synthesis. In the recent era DM is characterized by
dysfunctional signaling.  The fact that insulin crystals contain Zinc (49)
and this cation facilitated a supportive role in diabetes. Zinc, also has an
essential role in maintaining normal physiological function.(50,51)
Disturbances in Zinc homeostasis have been observed in diabetes (49,50-52)
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and many other chronic conditions like cancer (53,54), auto immune
disease(55,56), cardio vascular disease (57) and Alzhiemer’s disease.(58,59)
Zinc has a variety of  biological  implications like catalytic,
regulatory and structural.(60) Growth factors, cytokines, receptors,
enzymes and transcription factors belonging to cellular pathways contains
Zinc as a major cation.(61) Also it has a very essential role in numerous
cellular processes as a cofactor for more than 3000 human proteins
including nuclear factors, hormones and enzymes.(62) Mechanism that
modulate Zinc absorption, distribution, excretion and cellular uptake  are
very essential for normal cellular function. These processes are
maintained through various class of transport proteins that modulate the
uptake, efflux and compartmentalisation of Zinc.(63)
Recent studies shown that 4 metellothionines (MTs) 14 Zinc
importers (SLC 39/ZiPs) and 10 Zinc exporters (SLC 30/ZnTs) have been
described in mammals.(64) These metallothionines are the major Zinc
binding proteins that plays an important role in Zinc uptake , storage,
release and distribution.(65,66) The Zinc transporters are very important for
Zinc metabolism where the ZiP transporter contribute to a net increase in
cytosolic  Zinc , while the ZnTs cause a net decrease in cytosolic Zinc .
In 1980 ,Coulstan and Dandora (67) discovered that Zinc exerted a potent
stimulating effect upon lipogenesis in rat adipocytes independent of and
additive to that of insulin. These findings suggest that the effects of this
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cation may have physiological relevance in controlling insulin signaling
pathways since Zinc is essential for the crystallization of insulin in
hexameric complexes  and is cosecreted with insulin on exposure to high
glucose . Similarly May and Controggi(68), utilizing supra physiological
concentrations (250-1000micromol) of  Zinc chloride, revealed a role for
this cation in stimulating glucose transport and  oxidation incorporation
of glucose carbon into glyceride glycerol and glyceride –fatty acid and
inhibition of ritodrine stimulated lipolysis in rat adipocytes.
Some studies have suggested that Zinc as an inhibitor of  protein
tyrosine phosphatases (PTP) (69).  In  fact  inhibition  of   PTB 1  a  negative
regulator of insulin signaling activity ameliorates high fat diet induced
insulin resistance.(70) The mechanisms of insulin mimetic activity of Zinc
on glucose (71-75) and lipid metabolism have been demonstrated in various
studies. Cumulative evidence has revealed that Zinc as a direct signaling
molecule implicated in extra cellular signal recognition, second
messenger metabolism, protein kinase activity, protein
phosphorylation.(76) Zinc plays a dynamic role as a second messenger in
the control of insulin signaling and glucose homeostasis.(77)
Insulin is critically important anabolic hormone implicated in
maintaining normal blood glucose levels. Zinc mediates these effects in
part through the inhibition of protein tyrosine phosphatases which
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increases the net phosphorylation of insulin receptor and activates its
signaling cascade.
Zinc is an essential micro nutrient that is required for various
cellular function. Zinc is considered important because it plays a major
role in the stabilisation and synthesis of insulin hexamers and the
pancreatic hormones. It also has a potent anti-oxidant and anti-
inflammatory agent. Zinc may improve glycemia and restored normal
Zinc status in diabetic individuals may counteract the deleterious effects
of oxidative stess,helping to prevent complications associated with
diabetes.
Following are the important effects of Zinc on cellular
homeostasis:
1) Stimulation of glucose uptake,
2) Lipogenesis in adipocytes,
3) Tyrosine phosphorylation of the insulin / IGF-1 receptor and
insulin receptor substrate -1,
4) Activation of epidermal growth factor receptor,
5) Inhibition of PTP,
6) Activation of mitogen activated kinases (MAPKs),C- jun N-
terminal kinases,
7) Increase in glycogen synthesis.
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Molecular and cellular studies in animal models have shown that
Zinc plays an important role in the synthesis, storage and action of insulin
under normal physiologic conditions.
Coustan et al have demonstrated that Zinc stimulated lipogenesis in
rat adipocytes similarly to insulin.(78) In some another study insulin
secretion was potentiated following Zinc supplementation.(79) Dietary
Zinc supplementation in young mice for a period of 6 weeks showed
improvement in fasting hyperglycemia and hyper insulinemia. In humans
there is no definitive data about the role of Zinc in insulin resistance. All
patients with diabetes have low serum Zinc levels but this is likely to be
due to hyperZincuria (losing Zinc in the urine secondary to nephropathy
in diabetes) and impaired Zinc absorption.(80)  There is less degradation of
insulin when co administered with Zinc. Zinc is important in insulin
function. Studies have shown that diabetes is accompanied by
hypoZincemia and hyperZincuria.
The trace element Zinc is known to play an important role in
pancreatic islets as a specific structural component of the insulin
molecule and also in insulin secretion.(81) Zinc has been shown to possess
both antioxidant and anti-apoptotic properties. The availability of  Zinc is
controlled by two major families of transporters, the Zrt- and Irt-like
protein (ZIP) family (responsible for Zinc influx into cells) and the ZnT
family(responsible for intracellular transport of Zinc into organelles or
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Zinc efflux from cells). Whether alteration of Zinc transporters
contributes to stress and cell death during islet cell transplantation is
presently unknown. However, autoimmunity targeting Zinc transporter
proteins,  in  particular  the  ZnT  family  member  ZnT8,  has  action  and
carbohydrate metabolism. Polymorphisms for the same Zinc transporter
also confer risk in type 2diabetes (T2D). The highest Zinc content in the
body has been detected in the islets. Most of the intracellular Zinc is
stored with insulin in the insulin secretory vesicles in pancreatic ?-cells as
a Zinc insulin complex. The concentration of Zinc in these vesicles is
very high, approximately 20mM.(82) However, Zinc transporters are also
found in pancreatic ?-cells and are supposed to regulate glucagon
secretion.(83) During insulin secretion, Zinc is released together with
insulin into the extracellular islet space, and is taken up by neighboring
cells.(83) Within ?-cell insulin granules, each hexameric insulin crystal
contains two Zinc ions. (84) Zinc deficient rats have lower insulin
secretion andglucose uptake compared to normal rats.(85) Faure and
colleagues demonstrated that Zinc depletion decreased insulin activity in
rats.(85) Nutritional Zinc supplementation improved fasting insulinemia
and glycemia in rodents. The mechanism of action of Zinc, whether it
acts directly on insulin receptors and glucose transporters, or indirectly
via intracellular pathways of insulin, is unknown.(86) During insulin
exocytosis, insulin granules fuse with the ?-cell plasma membrane, and
release their content into the pancreatic micro-circulation.(87) The
important role of Zinc in pancreatic ?-cell function requires that these
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cells are equipped with specialised mechanisms to take up Zinc and
incorporate it into their secretory granules.(88)
FIG 3.3: ZINC AND ITS EFFECTS IN HYPERGLYCEMIA
Stimulation of pancreas - growth , insulin
synthesis
Stimulation of beta cells
            Immune-mediated free radical attack
Inhibition of xanthine oxidase preventing
lipoperoxidation
                                                               Inhibition of ROS (Haber Weiss cycle)
PDX-1
MA
SH (sulphydryl) group protein stabilization
                                                 Inducing metallothionine synthesis
   ZINC
                  GLUCOSE - HOMEOSTASIS
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Islet oxidative stress and Zinc as an antioxidant
Oxidative stress
Islets have considerably  higher proportion of pancreatic blood
supply compared with pancreatic acinar tissue, and this unit terribly
sensitive to hypoxia and hypoxia-induced oxidative stress. (89, 90) The
chronic hyperglycemia that happens in diabetes also causes oxidative
stress and promotes the formation of reactive oxygen species (ROS), (91)
leading to mitochondrial pathology,(92) endoplasmic reticulum stress, (93-95)
and finally leads to ?-cell dysfunction.(96) Oxidative stress additionally
plays a vital role in decreasing islet cell viability throughout isolation and
transplantation. (97) During islet transplantation procedures, islets undergo
hypoxia and decreased oxygen consumption .This initiates biochemical
reactions leading to the production of ROS, and subsequent damage and
injury to the islets [98, 99]. Increased oxidative stress in islets during this
period is partly due to decreased expression of antioxidant enzymes, such
as glutathione peroxidise, catalase, and xanthineoxidase. (100)
Zinc as an antioxidant :
The antioxidant properties of Zinc in organs like skin and lung
have been thoroughly investigated. However, the role of Zinc as
antioxidant in the pancreas has not been extensively studied. Disturbances
in Zinc homeostasis, and in particular Zinc depletion, in the pancreas
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have been associated with oxidative stress. (101) In  some  studies,  Zinc
supplementation has been found to reduce the progression and
complications of diabetes by reducing oxidative stress and apoptosis. (102-
104) Zinc plays an important role in the maintenance of the structural
integrity of copper Zinc superoxide dismutase (Cu-Zn SOD).(105) Zinc
supplementation increases superoxide dismutase activity in vitro.
Correspondingly, SOD activity in Zinc-deficient rats is decreased. Zinc
supplementation of Diabetic patients can prevent decreased synthesis of
the Zinc-containing antioxidant enzymes superoxide dismutase and
glutathione peroxidase, and thereby reducing the excretion of albumin in
micro albuminuric Diabetic patients. (106)Another catalyst important in
oxidative stress is xanthine oxidase, which catalyses the hydroxylation of
xanthine to form superoxide radicals. Zinc inhibits xanthine oxidase
activity in vitro, thereby reducing lipid peroxidation. (107) In humans,
Roussel and colleagues demonstrated that 30 mg/day of Zinc as
supplementation reduced lipid peroxidation within the blood samples. (108)
It was proposed that Zinc metallothionein complex inhibits xanthine
oxidase by interrupting the binding of iron in the Fenton reaction and
subsequent redox reaction. (109) In pancreatic islets, Zinc as a component
of Zinc metallothionein complexes provides protection against the
inflammatory reaction induced by multiple low doses of streptozotocin.
(110) Mechanistically, Zinc-upregulated metallothionein inhibits OH
generation by inhibiting the Fenton reaction through the binding of Fe2+.
Zinc is concerned in protecting sulfhydryl groups against oxidation and in
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inhibiting free radical production in the Haber Weiss cycle by competing
with transition metals. (110,111) By preventing proteins from oxidation, Zinc
contributes to sulphydryl [SH] stabilization . In summary, Zinc has
antioxidant properties mediated through SOD and metallotheionein
pathways protecting proteins from reactive oxygen species and free
radical attacks.
Zinc plays a fundamental role in the structural integrity of insulin.
The availability of Zinc is crucial for normal insulin formation and
secretion. Zinc also stabilizes the enzymes that protect against apoptosis.
It is thus an important antioxidant. Zinc transporters are also important
proteins, which regulate the availability of Zinc.
Zinc and its effect on lipids
Atherosclerosis is a chronic oxidative inflammatory disease
characterized by deposition of lipids in the artery wall and infiltration of
inflammatory cells. It is initiated, in part, by the interaction of oxidized
low-density lipoprotein (ox-LDL) with cells of the vascular wall.
Vascular oxidative stress is an important pathologic event in
atherosclerosis. When LDLs are oxidized, they are readily taken up into
macrophages, promoting foam cell formation and the development of
atherosclerotic plaque. Once developed atherosclerotic plaque may
remain stable or it may leads to rupture resulting in acute coronary
syndromes such as myocardial infarction.
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Oxidative stress is often defined as an imbalance of pro-oxidants
and antioxidants, which can be quantified in humans as the redox state of
plasma reduced glutathione/oxidized glutathione (GSH/GSSG). Plasma
GSH redox in humans becomes oxidized due to age, chemotherapy,
smoking, and in common diseases such as type 2 diabetes and
cardiovascular disease.
Zinc is an essential trace element that is vital in maintaining normal
physiology and cellular functions. It is one of the most abundant metals in
the human body, second to iron. The importance of Zinc is apparent from
the enormous number of proteins that contain Zinc ions in their structure.
Zinc has catalytic and structural functions in thousands of enzymes and
regulatory functions in a growing list of proteins. Ten percent of genes
encode Zinc-containing proteins. Because of its anti oxidant property it is
implicated in the prevention of atherosclerosis.
Knowledge about the requirements and importance in maintaining
the integrity of vasculature particularly the vascular endothelium is very
little. Zinc is required for normal cellular repair processes and also
atherosclerosis is believed to begin with endothelial cell injury, decreased
serum Zinc concentration in the vascular tissues may be involved in
either initiation of endothelial cell injury, potentiation of oxidative stress
and inflammatory response or inadequate protection against apoptosis.
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It also acts like anti atherogenic substance by interfering with the
signaling  pathways involved in apoptosis. It is very likely that certain
lipids and Zinc deficiency may potentiate the cytokine-mediated
inflammatory response and endothelial cell dysfunction in
atherosclerosis. The involvement of Zinc in the pathology of
atherosclerosis is not clear.
Zinc and its effect on weight :
FIGURE 3.4: ZINC AND ITS ROLE IN WEIGHT
Zinc acts as an assistant in weight control by a variety of ways.
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Firstly
Lack of Zinc affects the insulin receptors on the cells, so the blood
glucose levels go up,  the beta cells produce more insulin, which means
there is more unused insulin in the blood. As insulin promotes fat storage
having high levels will also cause  weight gain.
Secondly
Too much of copper can increase the conversion of glucose into
triglycerides. (Around the world, copper can be a problem because of an
increase in the use of copper water pipes for water distribution). This is
heavily increasing the intake of copper in many areas.
Zinc is what is known as a copper ‘antagonist’ or ‘competitor’ - in
other words it competes with copper both for absorption in the intestine
and for binding sites on albumin molecules. This causes lower levels of
copper and thus the production of fewer triglycerides. It has been found
that an excess of either of these two minerals leads to a deficiency in the
other.
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Thirdly
Leptin a hormone produced in the fat cells has been found to
regulate blood sugar by adjusting the amount of energy available. Lack of
Zinc decreases the blood levels of leptin. So it plays a role in appetite
control, storage of fat and amount of glucose stores in the liver.
TYPE 2 DIABETES - AN INFLAMMATORY DISEASE
Type 2 Diabetes is nowadays viewed as an auto inflammatory
disease. As evidenced by several studies, there are elevated levels of
acute phase proteins such as CRP, haptoglobin, Fibrinogen and also
cytokines and chemokines in Type 2 Diabetes .  It  is  also postulated that
Interleukin-1? and Interleukin -6 ,CRP are predictive of Type 2 Diabetes .
And also Interleukin 1 receptor antagonist are said to be increased in
obesity and in pre diabetic state in significant levels. These biomarker
levels are elevated if there are any associated Type 2 Diabetes with
complications either micro vascular or macro vascular. Adipose tissue is
a major site of production of inflammatory markers and presence of
excess of adipose tissue as in obesity initiates and leads to establishment
of inflammation in the body as depicted below.
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FIG 3.4 : DEVELOPMENT OF INFLAMMATION IN TYPE 2
DIABETES
Due to the inflammation, insulitis results and initial steps for Type
2 Diabetes are laid down .  In Type 2 Diabetes inflammatory mechanisms
said to be present are
1. Hypoxia
2. Adipocyte cell death
3. Metabolic stress--- Cytokine- NF-?B  and JNK pathway
4. IL- 6 and insulin resistance .
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Zinc has a concentration-dependent effect on peripheral blood
mononucleate cells (PBMC). It can inhibit or stimulate the assembly of
proinflammatory cytokines such as IL-1 and TNF-?. Zinc
supplementation of human PBMC leads to an increased messenger ribo
nucleic acid production and release of the cytokines IL-6, IL-1?, and
TNF-?.  On  the  other  hand,  several  studies  showed  that  Zinc  treatment
suppresses the formation of pro-inflammatory cytokines such as TNF-?,
IL-1? and IL-8 . Kee-Lung and colleagues showed that the result of Zinc
is concentration-dependent. (54) Zinc administration of 100 ?M stimulated
cytokine production and expression of caspase-3 and pro-apoptotic genes,
including Fas (FasL) and c-fos.  Zinc concentrations above 100 ?M
decreased cytokine stimulation and the expression of the anti-apoptotic
factors nuclear factor (NF) ?B, Bcl-2, and Bcl-XL in PBMC from healthy
subjects . (54)Zinc supplementation decreased TNF?-induced NF-?B
activity in PBMC. Zinc supplementation in cell lines upregulated anti-
apoptotic protein Zinc finger protein A20 in vitro . A20 inhibits the
activity of pro inflammatory cytokines via TNF receptor-associated
factors in cells . A20 is expressed in various cell types in response to a
number  of  stimuli,  such  as  TNF?,  IL1-?,  Epstein-Barr  virus  latent
membrane  protein,  and  others.  A20  inhibits  the  activation  of  NF-?B  by
IL-1? and TNF-? gene expression in endothelial cell. Cooper and
colleagues suggested that A20 may play a role in regulating gene
expression of IL-1?, IL-8, and TNF-? affected by Zinc .(60)
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In 2004 Hiroyuki YANAGISAWA studied Zinc deficiency and
clinical practice  and concluded that for Zinc deficiency treatment
30mg/day can be given.
In  2011  Priyanka  kunasekara  et  al  studied  effects  of  Zinc  and
multivitamin tablets on adult diabetes to evaluate the effects of Zinc with
or without other antioxidants on blood glucose, lipid profile, and serum
creatinine in adult diabetics on long-term follow-up and concluded that it
has beneficial effects in decreasing HbA1c levels in addition to elevating
serum Zinc levels.
In 2012 Jihye kim et al studied the effects of Zinc supplementation
on insulin resistance and metabolic risk factors  and  concluded that Zinc
supplementation has beneficial effects on insulin activity.
In 2012 Md.Rafiq Islam et al studied the association of  serum Zinc
level with Prediabetes and Diabetes   and concluded that serum Zinc level
is significantly lower in prediadetes when compared to healthy subjects.
In 2011 Mariea D Bosco et al studied  about  Zinc and Zinc
transporter regulation in pancreatic islets  and concluded that Zinc plays a
fundamental role in the structural integrity of insulin,  the availability of
Zinc is crucial for normal insulin function, secretion and it also stabilizes
the enzymes that protect against apoptosis.
In 2009 Qi Sun et al studied about the intake of Zinc in relation to
risk of type 2 diabetes  and concluded that higher Zinc intake may be
associated with  slightly lower risk of type 2 diabetes in women.
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In 2013 Priyanga Ranasinghe et al studied about Zinc
supplementation in pre-diabetes and concluded that the study will
provide a step change in the evidence guiding current and future policies
regarding dietary supplementation in prevention of diabetes.
In 2013 Saeed Akhtar et al studied prevalence of Zinc deficiency
and its health and economic consequences in South Asian developing
countries and concluded that Zinc deficiency in South Asian developing
countries is considerably prevalent. Populations from India, Nepal, Sri
Lanka, and Pakistan are also affected by Zinc deficiency. Inadequate
intake of Zinc has been regarded as one of the most significant causes of
Zinc deficiency.
In 2012 Stephen A. Myers et al studied about Zinc transporters,
mechanisms of action and therapeutic utility and implications for type 2
DM and concluded that Zinc transporters play a crucial role in insulin and
glucose metabolism.
In 2014 Foster et al studied that  Zinc transporter gene expression
and glycemic control in  women with type 2 DM and concluded that there
is an association between Type 2 DM and Zinc homeostasis.
In 2011 Ruz et al  studied  whether  Zinc has a potential coadjuvant
role in the therapy of  type 2 diabetes and concluded that Zinc
supplementation may have beneficial effects on glycemic control.
In 2007 Beletate et al studied  about  the  effect  of  Zinc
supplementation in the prevention of  type 2 DM and concluded  that
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there is currently no evidence to suggest the use of Zinc supplementation
in the prevention of type 2 DM. Future trials will have to standardise
outcomes measures such as incidence of type 2 DM, decrease of the
insulin resistance, quality of life, diabetic complications, all-cause
mortality and costs.
In 2013 Vashum p et al studied the association between the serum
Zinc levels with pancreatic beta cell function and insulin sensitivity in
pre-diabetic and normal individuals and concluded that higher serum Zinc
concentration is associated with increased insulin sensitivity.
In 2001 Anderson et al studied about the antioxidant effect of Zinc
and chromium in diabetic people and concluded that combined
supplementation provides better anti oxidant effect and glycemic control
in the diabetic population.
In  1986  Niewoehner  CB  et  al  studied  the  effect  of  Zinc
supplementation in diabetic people and concluded that Zinc deficiency
causes deranged immune function in diabetes.
In 2006 Al-Maroof RA et al studied to assess serum Zinc level in a
sample of diabetic patients (both type 1 and type 2 diabetics) in
comparison with those of apparently healthy controls and concluded that
Zinc supplementation decreases HbA1c levels significantly in diabetic
patients when compared to healthy subjects.
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In 2014 Mekwasan K et al studied the association between anti
cancer effect of Zinc in diabetic patients and concluded that Zinc has
beneficial effect.
In 2008 Xiang J et al studied about Zinc transporter and diabetes
and concluded that Zinc transporter has definite association with diabetes
and variations in this transporter leads to increased susceptibility to
diabetes.
In 2005 de Sena KC et al conducted a study to   identify the effect
of oral Zinc supplementation in patients with type 1 diabetes (T1DM) on
metabolic control and Zinc blood concentrations and concluded that
unsatisfactory results in diabetes.
In  2003  Roussel  et  al  studied  the  relationship  between  the
antioxidant effect and Zinc and concluded that Zinc has strong anti
oxidant effect in patients with diabetes.
In 2007 Islam et al studied the interactions between diabetes,
metallothionein and Zinc and concluded that Zinc enhances the synthesis
of metallothioneins which decreases the oxidative stress in patients with
diabetes.
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MATERIALS AND METHODS
POPULATION FRAME
Patients  attending  Medicine  OPD  in  ESI  PGIMSR  ,  KK   Nagar,
Chennai who  are newly diagnosed to have Type 2 Diabetes as per ADA
guidelines  were recruited. During  the study   all the new adult  patients
who  presented   to  the  OPD   with  complaints  of   easy  fatigability,
polyuria,  polyphagia, polydipisia or with risk factors for Diabetes or
referred  from  the  ESI   dispensary  after  the  initial  urine  glucose  test   or
from other allied departments were screened for Diabetes by HBA1C and
FBG. All the patients were screened and after meeting eligibility criteria
they were recruited in the study.
PERIOD OF STUDY
? 12 Months (2013-14)
DESIGN OF STUDY
 Placebo controlled, prospective, Randomized, double blinded
interventional study. Patients enrolled in the study were clearly instructed
not  to  vary their routine day to day activities and not to take any forms
of  Zinc supplementation other than what that has been given for the
study. The subjects were also asked to fast for a minimum of 8 hours
before coming to OPD for investigations.
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INCLUSION CRITERIA
1. Newly diagnosed Type 2 diabetic subjects without complications,
attending ESIC PGIMSR MEDICAL OPD ,KK Nagar,Chennai-78.
2. Age ? 20.
3. Gender – both male and female.
EXCLUSION CRITERIA
1. Type-1 Diabetes,
2. Type-2 diabetics with complications
3. Diabetes in pregnancy
4. Chronic kidney disease
5.  Chronic Liver Disease, Chronic Pancreatitis or IBD (Inflammatory
Bowel disease)
6. Subjects on Zinc supplementation, Immunomodulators drugs,
chelating drugs.
CONSENT
All patients were recruited in the study after getting consent in the
consent form in vernacular language. Consent form was approved by
Institutional Ethical Committee, ESI PGIMSR, KK Nagar.
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METHODS
All the new patients attending the OPD with risk factors for DM  or
the patients referred from ESI Dispensary  after urine glucose was
positive or from other departments were initially selected and after
getting consent regarding investigations and further inclusion in the
study, patients were subjected to FBG and HBA1C. After exclusion of
patients with IFG or IGT or with normal glucose  levels, remaining
patients of about 140 patients were subjected to Ultra sonogram abdomen
to rule out chronic kidney disease, chronic liver disease, fundus
examination to rule out Diabetic Retinopathy and ECG, Blood Urea
Sr.Creatinine, Urine routine examination along with early morning urine
microalbuminuria were done. After completing investigations 140
patients were divided randomly into two groups according to computer
generated random number. So each group consisted 70 patients .  Patient
groups are assigned as 1 and 2.
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• GROUP 1 (N=70) PLACEBO
Std drug metformin and / or
sulphonylurea
Placebo
• GROUP 2 (N=70) ZINC
Std Drugs  metformin and / or
sulfonylurea
Zinc supplement(50mg/day)
BBreakpoint for a patient
symptoms of zinc toxicity
abd pain,vomiting, and
severe diarrhoea
0 mth
3 mths
6 mths
1 time point
2time point
3 time point
Clinical parameters
CBC,FBG, PPBG, HbA1c,
Urea, Creatinine,
microalbuminuria
Lipid profile
Cholesterol, LDL,
HDL, TGL,VLDL
And zinc  levels
Anthropometry,ht,
Wt, BMI, WHR&
ECG,ECHO,Ophthalmi
c assessment
Electrolyte profile
Serum
calcium,po4
and ESR
TYPE 2 DM
METHODOLOGY
1 year 4 time point
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Investigation Profile :
Thorough history taking, vital signs, height, weight and clinical
examination done and were recorded from all the patients and entered in
the proforma. Body mass index calculation was also done.  Investigations
like HBA1C, FBG, PPBG, renal function tests, fasting lipid profile and
complete hemogram were entered in the proforma worksheet. 8 ml of
blood  was drawn in the fasting state and about  3 ml of blood in the post
prandial state, sample was stored in -200c, used for investigations.
Intervention:
Each subject  in group 2 was given Zinc tablets 50 mg  per day and
patients in Group 1 were given placebo tablets along with standard Oral
Hypoglycemic Agents  available in the hospital. Subjects are asked not to
change their routine activities and not to take any vitamin
supplementation other than the drug that was given. Subjects were also
instructed to come after three months to collect OHA and supplementing
drug and for review regarding any adverse effects and for monitoring of
the therapy and periodic telephonic communication was made for proper
compliance. Doses of  Zinc tablets were chosen after review of literature
on safe parameters.
At  the  end  of  six  months   history  during  the  trial,  state  of  well
being, height, weight, FBG, PPBG, HBA1C, Lipid profile, serum Zinc
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levels (as above), Haemogram, Urine analysis and micro albuminuria and
fundus examination were recorded and  data tabulated in proforma sheet.
GLUCOSE  : Kit used-Cobas C311
Test principle : Enzymatic  method with hexokinase
HB A1C
Hemoglobin A1c - determined by is Turbidimetric Inhibition
Immunoassay (TINIA) for hemolyzed whole blood.
Calculation of Results
The analyzer automatically calculates the serum Zinc concentration
in each sample by  using calibration curve. The results are expressed in
microg/dl.
STATISTICS
Descriptive statistics was done for all data and suitable statistical
tests of comparison were done. Continuous variables were analysed with
the Paired and Unpaired t test and categorical variables were analysed
with the Chi-Square Test and Fisher Exact Test. Statistical significance
was taken as P < 0.05. The data was analysed using EpiInfo software
(7.1.0.6 version; Center for disease control, USA) and Microsoft Excel
2010.
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Sample Size Calculation
Sample size was determined on the basis of a pilot study in which
the reduction in HBA1 c levels was measured at 10%.  We calculated a
minimum sample size of 70 patients was required in each group,
assuming a type 1 error (two-tailed) of 0.05 and a margin of error of 10%.
Therefore, the final sample selected was n=70 in Group 1 and n=70 in
Group 2.
The formula for calculating sample size is
n= t² x p(1-p)
m²
Description:
n = required sample size
t = confidence level at 95% (standard value of 1.96)
p = estimated prevalence of malnutrition in the project area
m = margin of error at 10% (standard value of 0.05)
n= (1.96)² x 0.1(1-0.9)
(0.05)²
n= 3.8146 x 0.09
0.025
= 138    = 69 per group
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RESULTS
140 patients were included after meeting eligibility criteria in the
study in two groups and followed for  a  period of  about  one year .  BMI,
FBG, PPBG, HBA1C, Serum Zinc Levels, Haemogram, Urine Routine
analysis and microalbuminuria were done and tabulated in the worksheet
and analyzed. Results are as follows:
Treatment Groups
Treatment
Groups
Name of
Group Treatment
Number of
Subjects
Group 1 Placebo
Placebo supplementation +
OHA  in newly detected type 2
diabetic patients
70
Group 2 Zinc
Zinc supplementation + OHA
in newly detected type 2
diabetic patients
70
Figure 5.1 : Age group comparison between patients
Lowest age in the study is 29 years and highest age in the study is 67.
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TABLE 5.1 AGE GROUP DISTRIBUTION BETWEEN GROUPS
Age
Distribution Placebo % Placebo %
21 to 30 3 4.29 3 4.29
31 to 40 10 14.29 14 20.00
41 to 50 31 44.29 33 47.14
51 to 60 23 32.86 13 18.57
61 to 70 3 4.29 7 10.00
Total 70 100 70 100
TABLE 5.2 MEAN AGE DISTRIBUTION BETWEEN GROUPS
Age (years) Placebo group Zinc group
N 70 70
Mean 48.17143 47.27143
SD 8.16669 8.890512
P value
Unpaired t test
0.533
              Mean age for placebo group is 48.17. Mean age for Zinc group is
47.27.p value for age difference between the groups is 0.533 (p<0.05)
which is statistically insignificant.
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Figure 5.2 Gender distribution between groups
TABLE 5.3 SEX DISTRIBUTION BETWEEN GROUPS
Gender
Distribution
Placebo % Zinc %
Male 33 47.14 34 48.57
Female 37 52.86 36 51.43
Total 70 100 70 100
In this study about equal distribution is noted between males and
females.
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TABLE 5.4  GENDER DISTRIBUTION BETWEEN GROUPS
Gender Distribution Placebo Zinc
Male 33 34
Female 37 36
Total 70 70
Chi squared 0.029
Degrees of freedom 1
P value Chi-square test without
Yates correction 0.8657
                p value for sex between the two groups by Chi square is
p=0.8657 which is statistically insignificant. Since age and gender is not
statistically significant, it means that there is no difference between the
groups. In other words the groups contain subjects with the same basic
demographic characteristics.
Figure 5.3 Comparison of  Pre BMI between groups
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TABLE 5.5 COMPARISON OF  PRE  BMI  TREATMENT
BETWEEN GROUPS
BMI Pre Treatment Placebo % Zinc %
<18.5 (Underweight) 0 0.00 1 1.43
18.5 to 24.9 (Normal
Weight) 15 21.43 15 21.43
25 to 29.9 (Overweight) 41 58.57 45 64.29
?30 (Obese) 14 20.00 9 12.86
Total 70 100 70 100
TABLE 5.6 COMPARISON OF  MEAN BMI PRE TREATMENT
IN BOTH GROUPS
BMI Pre Treatment Placebo Zinc
N 70 70
Mean 27.74514 27.97357
SD 3.050923 2.99396
P value Unpaired t test 0.131
p value for BMI (pre treatment)between the two groups by
unpaired t test  is 0.131 which is statistically insignificant.
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 Figure 5.4 Comparison of BMI post treatment between groups
TABLE 5.7 COMPARISON OF  BMI POST TREATMENT
BETWEEN BOTH GROUPS
BMI Post Treatment Placebo % Zinc %
<18.5 (Underweight) 0 0.00 1 1.43
18.5 to 24.9 (Normal
Weight)
13 18.57 14 20.00
25 to 29.9(Overweight) 39 55.71 45 64.29
?30 (Obese) 18 25.71 10 14.29
Total 70 100 70 100
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TABLE 5.8 COMPARISON OF MEAN BMI POST TREATMENT
IN BOTH GROUPS
BMI Post Treatment Placebo Zinc
N 70 70
Mean 27.97357 26.99729
SD 2.99396 3.770757
P value Unpaired t test 0.092167
            p value for BMI (post treatment)between the two groups by
unpaired t test  is 0.092167 which is statistically insignificant.
Hence age, sex , BMI during start and end of study doesn't interfere
with the variables to be measured.
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Figure 5.5 Comparison of FBG pre treatment in both groups
TABLE 5.9 FBG PRE TREATMENT (%) IN BOTH GROUPS
FBG Pre
Treatment
(mg/dl)
Placebo % Zinc %
? 110 0 0.00 0 0.00
111 to 140 28 40.00 30 42.86
> 140 42 60.00 40 57.14
Total 70 100 70 100
Most of  the subjects in both groups have  >140 mg/dl.
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TABLE 5.10 COMPARISON OF MEAN FBG AT PRE
TREATMENT IN BOTH GROUPS
FBG Pre Treatment Placebo Zinc
N 70 70
Mean 154.8 153.9
SD 22.314 30.021
P value Unpaired t test 0.828
         Mean FBG (pre treatment) in placebo group is 154.8.Mean FBG
(pre treatment) in Zinc supplemented group is 153.9. p value for FBG(pre
treatment)between the two groups by unpaired t test  is 0.828  which is
statistically insignificant.
Figure 5.6 Comparison of  FBG post treatment in both groups
12
37
21
0
5
10
15
20
25
30
35
40
? 110 111 to 140 > 140
N
um
be
r o
f S
ub
je
ct
s
FBG Groups inmg/dl
Comparison of  FBG post treatment in both groups
Placebo
Zinc
71
TABLE 5.11 FBG POST TREATMENT (%) IN BOTH GROUPS
FBG Post
Treatment
(mg/dl)
Placebo % Zinc %
? 110 3 4.29 12 17.14
111 to 140 31 44.29 37 52.86
> 140 36 51.43 21 30.00
Total 70 100 70 100
TABLE 5.12 COMPARISON OF  MEAN  FBG AT POST
TREATMENT IN BOTH GROUPS
FBG Post Treatment Placebo Zinc
N 70 70
Mean 145.3 131.8
SD 24.332 21.888
P value
Unpaired t test
0.0008
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Mean FBG (post treatment) in placebo group is 145.3. Mean FBG
(post treatment) in 131.8. p value for FBG(post treatment)between the
two groups by unpaired t test  is 0.0008  which is statistically significant.
The difference within the Zinc supplementation group (pre and
Post intervention) and fasting blood glucose levels is considered to be
statistically significant since p < 0.05(0.0008).
Figure 5.7 Correlation chart between Serum Zinc and FBG
(pretreatment)
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TABLE : 5.13 PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND FBG  (PRETREATMENT)
Pearson’s Correlation PRE-FBG mg/dl Interpretation
S.ZINC micro g/dl 0.17 Weak   positivecorrelation
P value 0.03                             Significant
P value by Pearson’s correlation between FBG and S.Zinc levels is
0.03 which is statistically significant. There is a weak positive correlation
is seen between FBG (pre treatment) and Serum Zinc levels.
Figure 5.8 Correlation chart between Serum Zinc and FBG (post
treatment)
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TABLE 5.14:  PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND POST -FBG
Pearson’s Correlation POST-FBGmg/dl Interpretation
POST S.ZINC mg/dl 0.152
Weak positive
correlation
P value 0.0001                    Significant
P value by Pearson’s correlation between FBG and S.Zinc levels is
0.0001 which is statistically significant. There is a weak positive
correlation is seen between FBG (post treatment) and Serum Zinc levels.
Figure 5.9 PPBG pre treatment comparison between groups
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TABLE 5.15 PPBG PRE TREATMENT (%) IN BOTH GROUPS
PPBG Pre
Treatment
(mg/dl)
Placebo % Zinc %
? 200 11 15.71 6 8.57
201 To 300 50 71.43 48 68.57
301 To 400 9 12.86 16 22.86
Total 70 100 70 100
TABLE 5.16 COMPARISON OF MEAN AT PPBG- PRE
TREATMENT IN BOTH GROUPS
PPBG Pre Treatment
(mg/dl)
Placebo Zinc
N 70 70
Mean 250.2 266.18
SD 44.66513 59.718
P value Unpaired t test 0.075
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Mean PPBG before treatment in placebo group is 250.2. Mean
PPBG before treatment in Zinc supplemented group is 266.18. p value for
PPBG(pre treatment)between the two groups by unpaired t test  is 0.075
which is statistically insignificant.
Figure 5.10 PPBG- post treatment comparison between groups
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TABLE 5.17 PPBG-POST TREATMENT (%) IN BOTH GROUPS
PPBG Post
Treatment
(mg/dl)
Placebo % Zinc %
? 200 4 5.71 21 30.00
201 To 300 64 91.43 47 67.14
301 To 400 2 2.86 2 2.86
Total 70 100 70 100
TABLE 5.18.COMPARISON OF MEAN PPBG AT POST
TREATMENT IN BOTH GROUPS
PPBG Post
Treatment
(mg/dl)
Placebo Zinc
N 70 70
Mean 234.2714 221.0143
SD 31.04224 40.80405
P value
Unpaired t test
0.032*
*Significant
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p value for PPBG(post treatment)between the two groups by
unpaired t test  is 0.032  which is statistically significant. The difference
within the treatment groups (pre and Post intervention) and post prandial
blood glucose levels is considered to be statistically significant since p <
0.05.
Figure 5.11 Correlation chart between Serum Zinc and PPBG
(pretreatment)
y = 0.064x + 67.61
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TABLE 5.19 PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND PPBG (PRETREATMENT)
Pearson’s Correlation PRE-PPBGmg/dl Interpretation
S.ZINC micro g/dl 0.18
Weak positive
correlation
P value 0.1487                Not significant
P value by pearson’s correlation between PPBG and S.Zinc
levels is 0.1487 which is statistically not significant. There is a weak
positive correlation is seen between PPBG (pre treatment) and Serum
Zinc levels.
Figure 5.12 Correlation chart between Serum Zinc and PPBG (post
treatment)
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TABLE 5.20 PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND PPBG  ( POST TREATMENT)
Pearson’s
Correlation Placebo Interpretation
                  Zinc -0.20575 Weak Negativecorrelation
              P value
     0.0003***                     Highly significant
*** Highly significant
P value by Pearson’s correlation between PPBG and S.Zinc
levels is 0.0003 which is statistically significant. There is a weak negative
correlation is seen between PPBG (post treatment) and Serum Zinc
levels.
Figure 5.13 Comparison of HBA1c Pre treatment in both groups
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TABLE 5.21 COMPARISON OF  HBA1C (%) BETWEEN
PLACEBO AND ZINC
HBA1c  Pre
Treatment Placebo % Zinc %
? 6 0 0.00 0 0.00
6.1 To 7 14 20.00 11 15.71
7.1 To 8 43 61.43 37 52.86
8.1 To 9 10 14.29 17 24.29
> 9 3 4.29 5 7.14
Total 70 100 70 100
TABLE 5.22 COMPARISON OF MEAN HBA1C PRE
TREATMENT  BETWEEN BOTH GROUPS
HBA1c  Pre Treatment Placebo Zinc
N 70 70
Mean 7.547 7.788
SD 0.617395 0.958129
P value
Unpaired t test
0.079
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Mean HBA1c level for placebo group is 7.547. Mean HBA1c level
for Zinc supplemented group is 7.788. p value for HBA1c(pre
treatment)between the two groups by unpaired t test  is 0.079  which is
statistically not significant.
Figure 5.14 Comparison of  HBA1c post treatment between both
groups
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TABLE 5.23 HBA1C LEVELS POST TREATMENT (%) IN BOTH
GROUPS
HBA1c  Post
Treatment Placebo % Zinc %
? 6 0 0.00 16 22.86
6.1 To 7 19 27.14 24 34.29
7.1 To 8 32 45.71 23 32.86
8.1 To 9 19 27.14 5 7.14
> 9 0 0.00 2 2.86
Total 70 100 70 100
TABLE 5.24 COMPARISON OF  MEAN HBA1C LEVEL POST
TREATMENT BETWEEN GROUPS
HBA1c  Post Treatment Placebo Zinc
N 70 70
Mean 7.415714 6.861714
SD 0.731018 1.032401
P value
Unpaired t test
0.0004***
*** Highly significant
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p value by unpaired t test between the two groups is 0.0004 which
is statistically significant. There is significant reduction in HBA1c levels
in Zinc supplemented group when compared to placebo.  The difference
within the treatment groups (pre and Post intervention) and HBA1c levels
is considered to be statistically significant since p < 0.05(0.0004).
Figure 5.15 Correlation chart between Serum Zinc and HBA1c
(pretreatment)
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TABLE 5.25 PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND HBA1C   ( PRE TREATMENT )
Pearson’s Correlation PRE-HBA1c % Interpretation
S.ZINC micro g/dl 0.1725 Weak positivecorrelation
P value        0.1881                     Not significant
P value by pearson’s correlation between HBA1c and S.Zinc levels
is 0.1881 which is statistically not significant. There is a weak positive
correlation is seen between HBA1c (pre treatment) and Serum Zinc
levels.
Figure 5.16 Correlation chart between Serum Zinc and HBA1c (post
treatment)
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TABLE 5.26 PEARSON’S CORRELATION COEFFICIENT
BETWEEN SERUM ZINC AND HBA1C  ( POST TREATMENT)
Pearson’s Correlation HBA1c-ZincPost Treatment Interpretation
Zinc -0.12639 Weak negativecorrelation
P value 0.0001***                 Highly significant
*** Highly significant
           P value by Pearson’s correlation between HBA1c and S.Zinc
levels is 0.0001 which is statistically significant. There is a weak negative
correlation is seen between HBA1c (pre treatment) and Serum Zinc
levels.
Figure 5.17 Comparison of  LDL pre treatment between both groups
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TABLE 5.27 COMPARISON OF LDL PRE TREATMENT  IN
BOTH GROUPS
LDL  Pre
Treatment
(mg/dl)
Placebo % Zinc %
? 100 33 47.14 24 34.29
101 To 150 36 51.43 35 50.00
151 To 200 1 1.43 8 11.43
> 200 0 0.00 3 4.29
Total 70 100.00 70 100.00
TABLE 5.28 COMPARISON OF MEAN LDL PRE TREATMENT
IN BOTH GROUPS
LDL  Pre Treatment Placebo Zinc
N 70 70
Mean 105.496 95.64
SD 24.92604 16.7486
P value
Unpaired t test
0.25515
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Mean LDL  pre treatment placebo group is 105.4. Mean LDL pre
treatment Zinc group is 95.64. p value for LDL between the two groups is
0.255 which is statistically insignificant.
Figure 5.18 Comparison of LDL post treatment in both groups
TABLE 5.29 COMPARISON OF LDL POST TREATMENT IN
BOTH GROUPS
LDL  Post
Treatment
(mg/dl)
Placebo % Zinc %
? 0.8 39 55.71 28 40.00
0.81 To 1 31 44.29 33 47.14
1.01 To 1.2 0 0.00 9 12.86
> 1.2 0 0.00 0 0.00
Total 70 100 70 100
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TABLE 5.30 COMPARISON OF MEAN LDL POST TREATMENT
IN BOTH GROUPS
LDL Post Treatment Placebo Zinc
N 70 70
Mean 95.64 109.37
SD 16.7486 27.36421
P value
Unpaired t test
0.50500
          The difference between the treatment groups and serum LDL levels
is  considered  to  be  statistically  not  significant  since  p  >  0.05.  So  the
effect of  Zinc supplementation on LDL levels in type 2 diabetic patients
is not significant.
Figure 5.19 Comparison of  TG pre treatment in both groups
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TABLE 5.31 COMPARISON OF  TG PRE TREATMENT IN BOTH
GROUPS
TG  Pre
Treatment Placebo % Zinc %
? 100 35 50.00 29 41.43
101 To 150 28 40.00 33 47.14
151 To 200 4 5.71 6 8.57
> 200 3 4.29 2 2.86
Total 70 100.00 70 100.00
TABLE 5.32 COMPARISON OF  MEAN TG PRE TREATMENT
IN BOTH GROUPS
TG  Pre Treatment Placebo Zinc
N 70 70
Mean 115.2986 109.0286
SD 40.48 32.35
P value
Unpaired t test
0.922
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Mean TG pre treatment placebo group is 115.2. Mean TG pre
treatment Zinc group is 109.02.  p value for TG between the two groups
is 0.922 which is statistically insignificant
Figure 5.20 Comparison of  TG post treatment in both groups
TABLE 5.33 COMPARISON OF   TG POST TREATMENT IN
BOTH GROUPS
TG  post
Treatment Placebo % Zinc %
? 100 36 51.43 32 45.71
101 To 150 29 41.43 32 45.71
151 To 200 2 2.86 5 7.14
> 200 3 4.29 1 1.43
Total 70 100 70 100
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TABLE 5.34 COMPARISON OF MEAN TG POST TREATMENT
IN BOTH GROUPS
TG Post Treatment Placebo Zinc
N 70 70
Mean 109.0286 112.1514
SD 32.35653 30.44071
P value Unpaired t test 0.55741
            The difference within the treatment groups (pre and Post
intervention) and serum triglycerides levels is considered to be not
statistically significant since p > 0.05 (0.55741).
FIGURE 5.21 COMPARISON OF  HDL (MG/DL) PRE
TREATMENT IN BOTH GROUPS
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TABLE 5.35 COMPARISON OF  HDL  PRE TREATMENT IN
BOTH GROUPS
HDL  Pre
Treatment Placebo % Zinc %
31 To 40 16 22.86 14 20.00
41 To 50 39 55.71 41 58.57
51 To 60 12 17.14 15 21.43
61 To 70 3 4.29 0 0.00
Total 70 100.00 70 100.00
TABLE 5.36 COMPARISON OF MEAN HDL AT PRE
TREATMENT IN BOTH GROUPS
HDL  Pre Treatment Placebo Zinc
N 70 70
Mean 46.54429 50.35429
SD 7.265097 7.159076
P value
Unpaired t test
0.528109
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Mean HDL pre treatment placebo group is 46.54. Mean HDL pre
treatment Zinc group is 50.35. p value for HDL between the two groups
is 0.5281 which is statistically insignificant
Figure 5.22 Comparison of   HDL post treatment in both groups
TABLE 5.37 COMPARISON OF  HDL (MG/DL)  AT POST
TREATMENT IN BOTH GROUPS
HDL  Post
Treatment Placebo % Zinc %
31 To 40 3 4.29 0 0.00
41 To 50 40 57.14 23 32.86
51 To 60 18 25.71 32 45.71
61 To 70 9 12.86 15 21.43
Total 70 100 70 100
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TABLE 5.38 COMPARISON OF MEAN HDL AT POST
TREATMENT IN BOTH GROUPS
HDL Post Treatment Placebo Zinc
N 70 70
Mean 50.35429 53.80571
SD 7.159076 7.205792
P value
Unpaired t test
0.5150
The difference between the treatment groups and serum HDL
levels is considered to be not statistically significant since p >
0.05(0.5150).
Figure 5.23 Comparison of  CHL pre treatment in both groups
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TABLE  5.39 COMPARISON OF CHL (MG/DL) AT PRE
TREATMENT IN BOTH GROUPS
CHL  Pre
Treatment
Placebo % Zinc %
? 100 0 0.00 0 0.00
101 To 150 6 8.57 5 7.14
151 To 200 44 62.86 46 65.71
> 200 20 28.57 19 27.14
Total 70 100.00 70 100.00
TABLE 5.40 COMPARISON OF MEAN CHL PRE TREATMENT
IN BOTH GROUPS
CHL  Pre Treatment Placebo Zinc
N 70 70
Mean 187.7434 172.1614
SD 29.96465 24.83353
P value
Unpaired t test
0.785016
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Figure 5.24 Comparison of  CHL (mg/dl) at  post treatment in both
groups
TABLE 5.41 COMPARISON OF  CHL (MG/DL) AT POST
TREATMENT IN BOTH GROUPS
CHL Post
Treatment Placebo % Zinc %
? 100 0 0.00 0 0.00
101 To 150 11 15.71 9 12.86
151 To 200 51 72.86 53 75.71
> 200 8 11.43 8 11.43
Total 70 100 70 100
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TABLE 5.42 COMPARISON OF MEAN CHL POST TREATMENT
IN BOTH GROUPS
CHL Post Treatment Placebo Zinc
N 70 70
Mean 172.1614 185.0286
SD 24.83353 121.1053
P value
Unpaired t test
0.386644
The difference within the treatment groups (pre and Post
intervention) and total cholesterol levels is considered to be not
statistically significant since p > 0.05. There is no effect of Zinc
supplementation in total cholesterol levels.
Figure 5.25 Comparison of  VLDL pre treatment in both groups
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TABLE 5.43 COMPARISON OF  VLDL PRE TREATMENT IN
BOTH GROUPS
VLDL  Pre
Treatment Placebo % Zinc %
? 20 17 24.29 22 31.43
21 To 30 30 42.86 31 44.29
31 To 40 16 22.86 13 18.57
> 40 7 10.00 4 5.71
Total 70 100.00 70 100.00
TABLE 5.44 COMPARISON OF  MEAN VLDL PRE
TREATMENT IN BOTH GROUPS
VLDL  Pre Treatment Placebo Zinc
N 70 70
Mean 28.02857 25.50571
SD 9.362354 8.199379
P value unpaired t test 0.206193
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Figure 5.26 Comparison of   VLDL post treatment in both groups
TABLE 5.45 COMPARISON OF  VLDL POST TREATMENT IN
BOTH GROUPS
VLDL Post
Treatment Placebo % Zinc %
? 20 20 28.57 28 40.00
21 To 30 33 47.14 34 48.57
31 To 40 11 15.71 4 5.71
> 40 6 8.57 4 5.71
Total 70 100 70 100
20
33
11
6
28
34
4 4
0
5
10
15
20
25
30
35
40
? 20 21 To 30 31 To 40 > 40
N
um
be
r o
f S
ub
je
ct
s
VLDL Groups inmg/dl
Comparison of VLDL Post Treatment in both
groups
Placebo
Zinc
101
TABLE 5.46 COMPARISON OF  MEAN VLDL POST
TREATMENT IN BOTH GROUPS
VLDL Post Treatment Placebo Zinc
N 70 70
Mean 25.50571 23.30571
SD 8.199379 7.489178
P value Unpaired t test 0.099704
Mean VLDL for placebo group is 25.50571. Mean VLDL for Zinc
group is 23.30571. The difference within the treatment groups (pre and
Post intervention) and serum VLDL levels is considered to be not
statistically significant since p > 0.05(0.0997).
TABLE 5.47 COMPARISON OF P VALUE FOR LIPID PROFILE
Lipid
Profile
Post-Treatment
P P valuevalueP
value
Pl
ac
eb
o
M
ea
n±
SD
Zi
nc
M
ea
n±
SD
LDL 95.64±16.75 109.37±27.36 0.50
TGL 109.03±32.36 112.15±30.44 0.55
HDL 50.35±7.16 53.81±7.21 0.51
CHL 172.16±24.83 185.03±21.11 0.38
VLDL 25.51±8.20 23.31±7.49 0.09
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From the table, it is evident that there is no significant difference in
the levels of LDL cholesterol, Triglycerides, HDL cholesterol, Total
cholesterol and VLDL cholesterol between the two groups. Hence there is
no significant change in lipid profile on Zinc supplementation to diabetic
individuals.
Figure 5.27 Comparison of  ESR at  pre treatment  in both groups
TABLE 5.48 COMPARISON OF  ESR  AT PRE TREATMENT IN
BOTH GROUPS
ESR  Pre
Treatment Placebo % Zinc %
? 15 11 15.71 14 20.00
15.1 To 20 11 15.71 21 30.00
20.1 To 25 19 27.14 12 17.14
> 25 29 41.43 23 32.86
Total 70 100.00 70 100.00
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TABLE 5.49 COMPARISON OF  MEAN  ESR PRE TREATMENT
IN BOTH GROUPS
ESR  Pre Treatment Placebo Zinc
N 70 70
Mean 25.98571 24.44286
SD 13.56305 13.13766
P value
Unpaired t test
0.062279
Figure 5.28 Comparison of  ESR at  post treatment in both groups
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TABLE 5.50 COMPARISON OF  ESR POST TREATMENT IN
BOTH GROUPS
ESR Post
Treatment Placebo % Zinc %
? 15 13 18.57 14 20.00
15.1 To 20 17 24.29 21 30.00
20.1 To 25 17 24.29 17 24.29
> 25 23 32.86 18 25.71
Total 70 100 70 100
TABLE 5.51 COMPARISON OF  MEAN  ESR POST
TREATMENT IN BOTH GROUPS
ESR Post Treatment Placebo Zinc
N 70 70
Mean 24.44286 21.3
SD 13.13766 8.022342
P value
Unpaired t test
0.090316
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The difference within the treatment groups (pre and Post
intervention) and ESR levels is considered to be not statistically
significant since p > 0.05(0.0903).
Figure 5.29 Comparison of  Serum Zinc pretreatment in both groups
TABLE 5.52 COMPARISON OF   SERUM ZINC (MICROGM/DL)
PRETREATMENT IN BOTH GROUPS
S. ZINC  Pre
Treatment Placebo % Zinc %
? 50 3 4.29 0 0.00
51 To 74 44 62.86 44 62.86
75 To 100 22 31.43 24 34.29
> 100 1 1.43 2 2.86
Total 70 100.00 70 100.00
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TABLE 5.53 COMPARISON OF  MEAN SERUM ZINC PRE
TREATMENT IN BOTH GROUPS
S. ZINC  Pre
Treatment Placebo Zinc
N 70 70
Mean 71.28571 70.9
SD 12.54458 11.16821
P value
Unpaired t test
0.382129
Figure 5.30 Comparison of  Serum Zinc post treatment in both
groups
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TABLE 5.54 COMPARISON OF  SERUM ZINC POST
TREATMENT IN BOTH GROUPS
S. ZINC Post
Treatment Placebo % Zinc %
? 50 1 1.43 0 0.00
51 To 74 49 70.00 38 54.29
75 To 100 19 27.14 29 41.43
> 100 1 1.43 3 4.29
Total 70 100 70 100
TABLE 5.55 COMPARISON OF  SERUM ZINC POST
TREATMENT IN BOTH GROUPS
S. ZINC Post
Treatment Placebo Zinc
N 70 70
Mean 70.9 76.11
SD 11.16821 11.32337
P value
Unpaired t test
0.006896***
*** Significant
Mean S.Zinc levels in post treatment placebo group is 70.9. Mean
S.Zinc levels post treatment Zinc group is 76.11. p value for S.Zinc levels
between the two groups is 0.00689 which is statistically significant.
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DISCUSSION
Zinc deficiency has been shown to be associated with progression
of diabetes and its supplementation has been shown to delay the
progression from prediabetic to diabetic stage. It has also been shown to
increase the insulin secretion. In vitro trials, have shown a strong
association between DM & Zinc in insulin secreting ? cells in pancreas
and  also  by  demonstrating  their  role  in  the  pathogenesis  of   Type  1  &
2DM. Trials relating to intervention with  Zinc to improve glycemic
parameters  and  its  outcome  are  small  in  number  and  their  results  are
conflicting.
This is because, all the studies which were conducted had
1. Small population which cannot be generalized to public,
2. Duration of the study was very small,
3. Zinc doses for DM was not specified and not uniform in these
studies,
4. Geographical factors which influence the study, as most of the
trials were conducted in western world
5. Race –most of the studies were conducted in white population.
109
More studies are needed to estimate the exact prevalence of Zinc
deficiency in both urban and rural India, which should be community
based. This is because our country has a population distinct from other
region of the world, by having  patients with diabetes with lean body
mass. Hence there is a need to evaluate Zinc’s clinical utility in T2 DM
which will be an effective , affordable, public health measure like iodine.
Trials have shown that Zinc supplementation   in patients with IGT
increases insulin secretion and its sensitivity and  some other trials have
shown that  there is   no benefit  of  supplementing  Zinc  in patients  with
complications  or   those  requiring  insulin  .  Hence   role  of  Zinc  and  its
mechanism to improve the glycemic state of newly detected Type 2
Diabetic patients has to be undertaken, as this group  of patients have
about 50% of the beta cell mass which if appropriately protected may
prevent or delay the complications.
In  our  study  Mean  age  of  the  subjects  was  included  with  placebo
group is 48.17 and Zinc group is 47.27. There is no significance between
the groups implying that there is about equal distribution in the Groups.
Lowest age in the study is 29 years and highest age 67 years. Maximum
number of patients were between the 41-50 years. There was about equal
distribution of  the male and female patient  about  1:1 ratio totally and in
all groups. These results were correlated with WHO statistics.
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Serum Zinc levels in most of the subjects in both groups were
below 75 microgm/dl before Zinc supplementation. After Zinc
supplementation Serum Zinc levels were significantly increased .
Statiscally this indicates that there is a true difference within the Zinc
supplementation group (pre and Post intervention) in relation to HBA1c
levels and the difference is significant.
FBG :
In simple terms, with Zinc supplementation in newly detected type
2 diabetic patients, the fasting blood glucose levels is reduced by 22
mg/dl in comparison with placebo which reduces fasting blood sugar
levels by 9.57 mg/dl with a p-value of 0.00079 according to unpaired t-
test. This indicates that there is a true difference within the Zinc
supplementation group (pre and Post intervention) in relation to fasting
blood glucose levels and the difference is significant.  The reduction in
fasting blood glucose levels was meaningfully more (17%) in the Zinc
supplementation group compared to the placebo group . This difference is
true and significant and has not occurred by chance. We conclude that
there is real advantage by addition of Zinc in newly detected type 2
diabetic patients, which in turn decreases the fasting blood glucose levels
significantly. Similar study was conducted by Jayawaradhane et al
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concluded that the pooled mean difference for FBG between Zinc
supplemented and placebo groups from random effects analysis was
?18.13 mg/dl.(95% CI:–33.85,–2.41; p<0.05).
Another study done by Priyanka Gunasekara et al concluded that
Zinc and supplementation showed beneficial effects in the metabolic
control of adult diabetics in addition to elevating their serum Zinc level.
PPBG :
In simple terms, with Zinc supplementation in newly detected type
2 diabetic patients, the post prandial  blood glucose levels is reduced by
45 mg/dl in comparison with placebo which reduces post prandial blood
sugar levels by 16 mg/dl with a p-value of 0.0323 according to unpaired
t-test. The reduction in post prandial blood glucose levels was
meaningfully more (61%) in the Zinc supplementation group compared to
the placebo group. This indicates that there is a true difference within the
Zinc supplementation group (pre and Post intervention) in relation to post
prandial blood glucose levels and the difference is significant.  This
difference is true and significant and has not occurred by chance. We
conclude that there is real advantage by addition of Zinc in newly
detected type 2 diabetic patients, which in turn decreases the post prandial
blood glucose levels significantly.
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HBA1c :
Zinc supplementation in newly detected type 2 diabetic patients,
the HBA1c levels is reduced by 0.95% in comparison with placebo which
reduces HBA1c levels by 0.25% with a p-value of 0.00036 according to
unpaired t-test. The reduction in HBA1c levels was meaningfully more
(79%) in the Zinc supplementation group compared to the placebo group
by 0.097 %. This difference is true and significant and has not occurred
by chance. We conclude that there is real advantage by addition of Zinc
in newly detected type 2 diabetic patients, which in turn decreases the
HBA1c levels significantly.
Lipid profile :
The difference within the treatment groups (pre and Post
intervention)  and  serum  VLDL,  TG,  CHL,  HDL,  LDL  levels  is
considered to be not statistically significant since p > 0.05.
BMI has not changed significantly after supplementation of Zinc
(p=0.186). BMI in pre interventional and post interventional groups was
27.97 and 26.99 respectively. Jihye kim et al showed that BMI did not
change  after  Zinc  supplementation.  This  has  been  well  correlating  with
our results.
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ESR has also shown no significance after Zinc supplementation.
Other parameters like renal function test, Hemogram have also shown no
significant association after supplementation of Zinc. Trials which have
been conducted earlier too did not show statistically significant
improvement in lipid profile or other parameters.
114
LIMITATIONS OF THE STUDY
1. The  sample  size  was  too  small  to  extrapolate  it  to  general
population.
2. The follow up period was short.
3. The efficacy of Zinc as monotherapy could not be evaluated due to
ethical considerations.
4. Variations in baseline parameters such as serum Zinc status, blood
glucose and lipid levels.
5. Differences in Zinc doses, formulae, sample sizes and study
durations.
6. Limited availability of data on Zinc intake from other sources such
as diet.
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CONCLUSION
Zinc supplementation improves glycemic parameters HbA1C,
FBG, PPBG in newly detected Type 2 Diabetics when compared to
placebo group.Thus, it appears that the beneficial effects of Zinc
supplementation on metabolic parameters can be seen mainly in
individuals with Zinc deficiency or diseases causing Zinc deficiency such
as diabetes.
In our study, which was done on newly detected Type 2 DM
patients OHA and Zinc supplementation have shown better  glycemic
control than in placebo group with similar control of FBG & PPBG in
Group 2 who received 50 mg/day. HbA1C also shows significant
decrease in Group 2 compared to placebo Group  after 6 months of
supplementation with a p 0.00036 (<0.05). Zinc supplementation with
oral hypoglycemic agents may provide better glycemic control. There is
no significant effect on fasting lipid profile after Zinc supplementation.
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B´Ä £ØÔ¯ uPÁÀ £iÁ® ©ØÖ®
B´ÂÀ £[÷PØ£uØPõÚ J¨¦uÀ £iÁ®
öuõÈ»õÍº {» Põ¨¥mk ©¸zxÁ©øÚ ©ØÖ®
©¸zxÁ £mh ÷©Ø£i¨¦ Bµõ´a] |ÖÁÚ®,
Pø»bº P¸nõ|v {Pº,
ö\ßøÚ & 600 078.
(2013 & 2014)
C¢u¨ £iÁ® ö\ßøÚ P.P. {P¶À EÒÍ öuõÈ»õÍº {» Põ¨¥mk
©¸zxÁ©øÚ ©ØÖ® ©¸zxÁ £mh ÷©Ø£i¨¦ Bµõ´a] |ÖÁÚzvÀ
ö£õx  ©¸zxÁz  xøÓ°ß  öÁÎ  ©ØÖ®  EÒ  ÷{õ¯õÎ  ¤¶ÄPÎÀ
B÷»õ\øÚ ö£Ó Á¸® ÷{õ¯õÎPÎÀ \ºUPøµ ÷{õ°ÚõÀ £õvUP¨£mh
÷{õ¯õÎPÎß “}¶ÈÄ ÷{õ´US â[U GßÝ® \zx ©õzvøµPøÍ
£¯ß£kzxÁuß ö\¯ÀvÓøÚ J¨¤k®”. C¢u B´øÁ öuõÈ»õÍº {»
Põ¨¥mk ©¸zxÁ©øÚ ©ØÓ® Bµõ´a] |ÖÁÚzvÀ ö£õx ©¸zxÁz
xøÓ°À £mh ÷©Ø£i¨¦ £°¾® ©¸.S.A¸sS©õº ¬ußø©
Bµõ´a]¯õÍµõP C¢u B´øÁ {hzxQßÓõº. ÷£µõ.©¸.©õ»v,
xøÓzuø»Áº (ÁÈPõmi) AÁºPÒ ÁÈ {hzxQßÓÚº.
£[÷PØ£õÍ¶ß ÷uºÄ ¬øÓ
 u[PøÍ C¢u B´ÂØS Em£kzx® ¬ß¦ ¬Êø©¯õP £¶÷\õvzx
uõ[PÒ \ºUPøµ ÷{õ°ÚõÀ £õvUP¨£mi¸¨£øu EÖv ö\´u ¤ÓS C¢u
B´øÁ ÷©ØöPõÒ÷Áõ®.
©Ö¨£uØPõÚ E¶ø©
 C¢u B´ÂÀ uõ[PÒ £[÷PØ£x ¬ØÔ¾® E[PÒ ©Ú©õº¢u
Â¸¨£®. C¢u B´ÂÀ £[÷PØP ©Ö¨£vÚõÀ u[PÐUS
÷©ØöPõsk QøhUS® ]Qaø\ ©ØÖ® ÷\øÁ°À GÆÂu ©õØÓ¬®
C¸UPõx.
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{øh¬øÓPÒ
}[PÒ C¢u B´ÂÀ £[÷PØP Â¸¨£® öu¶ÂzuõÀ {õ[PÒ
E[PÐøh¯ \ºUPøµ ÷{õ°øÚU SÔzuõÚ ]» ÂÁµ[PøÍ
÷PmhÔ÷Áõ®.
 }¶ÈÄ ÷{õ´ C¨÷£õx {õmiß ªP¨ ö£¶¯ \¬uõ¯ ÷{õ¯õP
©õÔÁ¸QÓx. C¢u ÷{õ°ß ÂøÍÄPÍõÀ C¸u¯®, - øÍ, ]Ö}µP®,
Ps£õºøÁ £õv¨£xhß AuØS¶¯  ©¸zxÁ ]Qaø\PÍõÀ {õk®
Ãh® _ø©¯õQÓx. GÚ÷Á ¦v¯ ©¸zxÁ ¬øÓPøÍ Bµõ´¢x
PshÔ¯ ÷Ási¯ `Ç¼À {õ® C¸UQß÷Óõ®.
 â[U  GßÝ®  uõx¨  ö£õ¸Ò  {®  Eh¾US  ªPÄ®
CßÔ¯ø©¯õuuõS®. Czuõx ö£õ¸Ò £À÷ÁÖ ÁÈ¬øÓPÎß - »®
CµzuzvÀ \ºUPøµ°ß AÍøÁU Pmk¨£kzxÁuõP £À÷ÁÖ
B´ÄPÒ öu¶ÂUQßÓx. C¢u B´Âß - »® â[U ©õzvøµPÒ
vÚ\¶ 50 ª.Q. Áõ´ ÁÈ¯õP 6 ©õu[PÒ Áøµ \õ¨¤mk, \ºUPøµ°ß
AÍøÁ PshÔ÷Áõ®. ]» ÷{µ[PÎÀ £]°ßø©, Áõ¢v, ©¯UP®,
©»a]UPÀ ÷£õßÓøÁ GØ£h»õ®. AÆÁõÖ GØ£mhõÀ Eh÷Ú
©¸zxÁøµ AqP ÷Ásk®.
 C¢u B´ÂÀ P»¢x öPõÒÁx JÆöÁõ¸Á¸øh¯Á¶ß ö\õ¢u
Â¸¨£®.  C¢u  B´Ä  BÖ  ©õu[PÒ  {øhö£Ö®  ©ØÖ®  ]»  ]Ó¨¦
Cµzu  £¶÷\õuøÚPÒ  B´ÂÀ  ö\´¯¨£h  EÒÍÚ.  CuØS  8ª¼
Cµzu®  3  ©õuzvØS  J¸  ¬øÓ  AÎUP  ÷Ási  Á¸®.  C¢u
£¶÷\õuøÚPÒ - »® uõß u[PÒ \ºUPøµ ÷{õ´ ©ØÖ® â[U
AÍÄPÒ PsPõoUP¨£h EÒÍÚ.
A£õ¯[PÒ GßÚ
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 C¢u B´Âß - »® E[PÐUS G¢u £õv¨¦® HØ£h
Áõ´¨¤Àø». ©õÓõP {ßø© £¯US® JßÓõP C¸US®.
{ßø©PÒ
“}¶ÈÄ ÷{õ´US  â[U GßÝ® \zx ©õzvøµPøÍ
£¯ß£kzxÁuß ö\¯ÀvÓøÚ J¨¤k®”. C¢u B´øÁ ÷©ØöPõÒÁuß
ÂøÍÁõP  ¤ßÁ¸®  PõÀ[PÎÀ  }µÈÄ  ÷{õ´  ]Qaø\°À  â[U
©õzvøµPøÍ öuõhº¢x £¯ß£kzxÁuØPõÚ ÁÈxøÓPøÍ Psk¤iUP
ÁÈÁøP EÒÍx.
¯õøµ öuõhº¦ öPõÒÁx
 E[PÐUS  \¢÷uP®  HuõÁx  C¸¢uõÀ  C¨÷£õx  AÀ»x  ¤ßÚ¸®
÷PmP»õ®. }[PÒ C¢u öuõÈ»õÍº {» Põ¨¥mk ©¸zxÁ©øÚ ©ØÖ®
©¸zxÁ £mh÷©Ø£i¨¦ Bµõ´a] |ÖÁÚzvÀ ö£õx ©¸zxÁz xøÓ°À
¬xPø» £°¾® ©¸.S.A¸sS©õº, ÷{µi¯õP÷Áõ AÀ»x ö\À :
9176213210 GßÓ GsoÀ öuõhº¦ öPõÒÍ»õ®.
 uPÁÀ  £iÁzvÀ  C¸¢u  uPÁÀPøÍ  £izx  AÔ¢÷uß  /  £iUP
÷PmhÔ¢÷uß. GßÝøh¯ \¢÷uP[PøÍ wºzxUöPõÒÍ
Áõ´¨£ÎUP¨£mhx. GÚUS 18Áx Á¯vØS ÷©À BÁuõÀ C¢u B´ÂÀ
P»¢xöPõÒÍ GÆÂu u¯UP¬®, ÁØ¦Özu¾® CÀ»õ©À ¬Ê©Úxhß
J¨¦uÀ AÎUQ÷Óß.
£[÷PØ£õÍ¶ß ö£¯º   B´Ä ÷©ØöPõÒ£Á¶ß ö£¯º
£[÷PØ£õÍ¶ß øPö¯õ¨£®   B´Ä ÷©ØöPõÒ£Á¶ß øPö¯õ¨£®
÷uv  :      ÷uv  :
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PRE INTERVENTION GROUP
SL.
NO IP NO
GR
OU
P
AGE
(YE
ARS
)
S
E
X
PRE-
BMI
PRE-
FBG
mg/dl
PRE-
PPBG
mg/dl
PRE-
HBA1c
%
PRE-
Urea
mg/dl
PRE-
Creat
mg/dl
PRE-
LDL
mg/dl
PRE-
TG
mg/dl
PRE-
HDL
mg/dl
PRE-
CHL
mg/dl
PRE-
VLDL
mg/dl
PRE-
Hb %
PRE
WBC/
Cu
mm
PRE-
PLT
cells/
cumm
PRE-
ESR
mm/hr
PRE-
Urine
glucos
e
PRE-U
micro
albumin
mg/l
S.ZINC
micro
g/dl
1 15802407 1 45 F 27.53 140 220 7.6 18 0.8 56.8 85.7 49.1 123 17
10.20
% 6400 241000 21 0 3.22 56
2 13262803 1 39 F 21.06 166 259 6.9 27 0.3 59 83 38 190 23 11.6 7000 293000 45 0 6.8 60
3 21169635 1 50 M 28.53 154 271 7.8 39 0.5 139 130 49 203 34 12 4500 270000 45 1 7.6 65
4 15418904 1 38 F 27.23 160 287 6.9 40 0.56 88 97 48 240 24 9 4600 214000 34 0 6.23 69
5 15460918 1 29 M 26.6 180 300 8.5 18 0.65 129 110 49 228 24 14 5000 250000 39 0 7.6 70
6 1953258 1 49 F 30.8 176 323 6.7 49 0.68 90 98 62 204 36 13 4600 232000 35 1 6.7 89
7 17220654 1 46 F 29.06 154 254 6.8 30 0.67 120 98 46 254 48 12 6100 256000 34 1 1.45 90
8 13694195 1 47 M 32.04 197 264 7.2 28 0.45 109 87 49 287 34 10 5600 314000 21 0 6.5 45
9 15671377 1 56 F 23.53 152 275 7.8 32 0.62 98 119 41 187 29 12 4900 303000 23 0 8.6 50
10 11886089 1 58 M 33.53 173 286 6.9 33 0.56 107 97 60 164 26 11 5600 234000 32 0 1.4 70
11 15246133 1 65 F 33.98 183 265 6.5 39 0.44 111 86 48 184 56 13 5400 214000 24 1 7.8 65
12 17770034 1 35 M 26.68 179 275 6.8 34 0.56 129 98 52 194 45 10 6000 360000 22 1 2.24 49
13 21137046 1 56 F 28.88 129 285 7.3 35 0.67 149 134 45 190 39 9 4600 298000 9 0 7.8 56
14 12846025 1 67 F 29.41 153 298 8.5 17 0.44 139 129 39 168 40 13 9000 360000 23 1 5.6 78
15 14644613 1 57 M 27.08 189 198 7.5 19 0.35 138 278 40 183 35 11 6200 240000 28 0 1.48 77
16 12233560 1 58 F 23.13 192 204 9.1 23 0.43 140 249 35 187 31 9.8 5900 250000 16 2 5.67 65
17 13890074 1 54 M 28.15 175 208 8.7 29 0.74 130 143 31 180 29 9.3 5600 290000 29 1 8.6 64
18 11935914 1 60 F 29.41 196 280 8.1 30 0.79 89 160 48 190 33 10.5 11000 234000 98 0 5.64 109
19 12817186 1 54 F 27.41 163 276 8.3 33 0.39 96 96 38 198 45 10.4 6200 240000 11 1 5.6 98
20 21668962 1 48 M 31.95 183 289 8.4 32 0.75 90 98 59 178 49 11 5900 320000 31 0 8.6 90
21 20026778 1 54 F 23.33 180 298 8.5 33 0.77 97 93 45 193 19 9 8900 350000 19 1 5.9 76
22 21668926 1 44 F 26.6 140 222 7.5 18 0.8 56.8 85.7 49.1 123 17 10.2 6400 241000 21 1 3.22 69
23 20026877 1 38 M 30.08 129 258 6.9 14.6 0.55 139.6 83.4 38.2 173.52 17 11 7600 294000 49 0 6.88 72
24 12597961 1 38 M 29.06 138 345 7.8 27 0.58 88 130 48 160 21 11.3 5500 250000 34 0 7.88 75
25 20393376 1 50 F 32.46 134 196 7.08 28 0.76 129.6 97.3 46.3 157 23 10.9 6900 234000 28 0 4.67 65
26 21628703 1 44 M 23.53 178 320 8.5 30 0.9 90 110 44 180 20 10.8 8000 300000 45 2 8.98 67
27 17151241 1 47 F 33.98 131 195 7.15 28 0.62 129 96 62 224 19 13.2 9000 318000 10 0 11.16 65
28 16644988 1 40 M 26.85 145 212 7.2 21.1 0.56 121 87 46 187 18 14.8 5700 309000 29 1 6.98 64
140
29 117211049 1 49 M 28.88 140 187 7.4 19 0.43 127 136 49 208 27 10.8 7200 253000 21 0 7.66 79
30 13266624 1 47 F 29.41 134 230 6.9 24 0.56 124 146 41.6 214 17.6 13.2 8100 314000 30 1 6.82 56
31 17211049 1 29 M 27.08 176 248 7.8 34 0.51 120 85.2 60 204 17 11.7 10500 331000 22 0 5.6 79
32 13664566 1 46 F 23.18 156 246 7.3 28 0.42 76 84 48 164 28 14.3 7200 214000 34 1 9.46 86
33 17211049 1 47 M 31.95 140 240 7.8 40 0.67 78 86 52 184 25 13 4400 303000 6 0 6.7 76
34 13226656 1 56 F 23.66 130 210 7.1 24 0.48 104 98 45 194 30 14.3 6800 310000 20 0 7.8 64
35 17211049 1 43 M 26.83 134 188 6.98 21 0.71 98 134 39 194 26 14.2 8000 288000 22 0 8.66 60
36 14499464 1 57 F 28.04 194 315 9.1 25 0.61 95 278 40 190 56 12.3 12300 300000 18 0 6.5 59
37 14431445 1 52 M 28.88 160 280 7.8 16 0.76 80 101 35 168 27 13.1 8000 273000 28 0 1.48 54
38 20718112 1 53 F 27.58 132 167 6.8 13 0.67 125 135 31 183 27 14 10400 399000 9 0 2.24 67
39 16798901 1 45 F 29.47 160 292 7.4 33 0.8 100 130 48.5 180 25 10.4 9800 312000 16 2 13.8 60
40 16075225 1 52 F 23.11 159 208 7.71 11.1 0.79 78 105 38.3 170 33 14.3 6900 219000 11 1 3.56 99
41 21639157 1 48 M 27.39 158 225 7.12 34 0.69 89 176 59.4 189 25 11.7 5000 275000 31 0 5.67 77
42 20855170 1 50 F 26.48 166 248 7.41 19 0.68 96 88 45 156 17 11.1 7800 283000 19 0 8.64 75
43 16798901 1 35 M 24.99 126 210 7.1 14 0.5 70 76 48 140 12 11 6800 310000 12 1 6.8 72
44 16015225 1 50 M 28.25 155 335 7.9 18.6 0.77 156 123 51.4 232 24.6 15.3 7500 240000 19 0 7.47 65
45 21639157 1 41 M 31.16 126 186 7.1 23.9 0.75 102 176 48 210 35 11.8 6900 345000 14 0 7.8 69
46 20855170 1 48 F 27.04 147 240 7.6 20.7 0.7 115 115 44 232 33 11.4 6700 378000 13 0 8.99 59
47 1459800 1 38 M 23.61 162 320 8.2 28 0.45 80 120 52 230 32 13 6500 236000 24 1 6.7 88
48 12831804 1 44 M 24.38 210 314 9.2 32 0.48 82 122 54 180 28 12.3 9700 345000 22 1 8.4 87
49 14595800 1 58 F 26.83 132 274 7.1 18 0.62 113 68 34 140 22 10.8 4800 332000 17 1 4.2 83
50 12838104 1 39 F 27.43 210 234 7.8 32 0.54 142 152 54 228 32 11.4 9100 310000 25 2 4.4 86
51 21665478 1 44 M 28.9 146 294 7.6 28 0.48 122 103 38 134 24 8.3 4900 322000 20 1 3.28 82
52 14385636 1 56 M 23.22 162 243 8 26 0.61 64 104 48 206 26 9.4 4800 302000 21 0 4.67 86
53 21283778 1 48 F 30.08 128 216 7.1 18 0.54 94 108 48 168 19 9.6 7400 318000 32 0 4.21 75
54 16648686 1 47 M 29.06 146 264 7.6 28 0.7 76 88 44 170 18 12.8 7600 210000 45 0 5.6 65
55 21309276 1 48 F 32.46 130 210 7.6 36 0.64 130 117 42 198 31 12.2 7400 314000 24 1 12.6 58
56 20522554 1 63 F 23.53 148 230 7.45 24 0.6 110 100 48 180 26 13.1 7600 378000 18 0 8.88 69
57 16317857 1 29 F 33.98 140 222 7.5 18 0.84 56.8 85.7 49.1 123 18 10.2 6400 391000 21 1 3.22 70
58 20522554 1 46 M 26.85 129 258 6.9 14.6 0.74 139.6 83.4 38.2 173.52 20 11 7600 230000 49 0 6.88 60
59 16317857 1 47 F 28.88 138 345 7.8 27 0.78 88 130 48 160 19 11.3 5500 139000 34 1 7.88 64
60 17642561 1 53 M 29.41 134 196 7.08 28 0.75 129.6 97.3 46.3 157 23 10.9 6900 200000 28 0 4.67 72
61 20758111 1 43 F 27.08 178 320 8.5 30 0.8 90 110 44 180 28 10.8 8000 314000 45 1 8.98 61
141
62 20319047 1 57 M 23.18 131 195 7.15 28 0.64 129 96 62 224 25 13.2 9000 214000 10 0 11.16 70
63 20522541 1 52 F 31.95 145 212 7.2 21.1 0.64 121 87 46 187 37 14.8 5700 321000 29 0 6.98 69
64 21787011 1 53 M 23.66 140 187 7.4 19 0.44 127 136 49 208 26.8 10.8 7200 222000 21 0 7.66 64
65 20640387 1 45 F 26.83 134 230 6.9 24 0.83 124 146 41.6 214 35 13.2 8100 290000 30 0 6.82 88
66 22008912 1 56 M 28.04 176 248 7.8 34 0.5 120 85.2 60 204 29 11.7 10500 301000 22 0 5.6 79
67 20640387 1 38 F 24.38 156 246 7.3 28 0.5 76 84 48 164 41 14.3 7200 333000 34 1 9.46 72
68 21787011 1 45 M 26.83 140 240 7.8 40 0.65 78 86 52 184 18 13 4400 312000 6 0 6.7 63
69 20640387 1 58 F 27.43 130 210 7.1 24 0.86 104 98 45 194 25 14.3 6800 340000 20 1 7.8 64
70 22008912 1 51 M 28.9 134 188 6.98 21 0.56 98 134 39 194 23 14.2 8000 300000 22 0 8.66 91
71 21767662 2 44 M 29.06 194 315 9.1 25 0.76 95 278 40 190 38 12.3 12300 244010 18 0 6.5 82
72 17130038 2 38 M 27.23 160 280 7.8 16 0.79 80 101 35 168 36 13.1 8000 480000 28 0 1.48 74
73 11189548 2 38 F 27.41 132 167 6.8 13 0.48 125 135 31 183 34 14 10400 218000 9 0 2.24 81
74 21137719 2 50 F 27.58 160 292 7.4 33 0.93 100 130 48.5 180 22 10.4 9800 262000 16 1 13.8 64
75 15583252 2 44 M 28.08 159 208 7.71 11.1 0.68 78 105 38.3 170 19 14.3 6900 311000 11 0 3.56 63
76 11989862 2 47 F 26.42 158 225 7.12 34 0.73 89 176 59.4 189 11 11.7 5000 164000 31 0 5.67 66
77 17124908 2 40 M 40.95 166 248 7.41 19 0.49 96 88 45 156 34 11.1 7800 230000 19 0 8.64 61
78 21859096 2 49 F 26.83 126 210 7.1 14 0.48 70 76 48 140 31 11 6800 191000 12 1 6.8 62
79 21895069 2 47 F 33.33 155 335 7.9 18.6 0.68 156 123 51.4 232 65 15.3 7500 373000 19 0 7.47 59
80 12739185 2 29 F 20.19 126 186 7.1 23.9 0.62 102 176 48 210 19 11.8 6900 318000 14 0 7.8 60
81 11346370 2 46 M 35.65 147 240 7.6 20.7 0.65 115 115 44 232 48 11.4 6700 256000 13 0 8.99 59
82 16648686 2 47 M 25.96 162 320 8.2 28 0.43 80 120 52 230 16 13 6500 216000 24 1 6.7 61
83 16888211 2 53 F 25.68 210 314 9.2 32 0.71 82 122 54 180 30 12.3 9700 280000 22 1 8.4 71
84 16595726 2 43 F 28.34 132 274 7.1 18 0.46 113 68 34 140 32 10.8 4800 269000 17 1 4.2 61
85 21249528 2 57 F 31.64 210 234 7.8 32 0.6 142 152 54 228 34 11.4 9100 282000 25 1 4.4 62
86 17037224 2 52 M 25.77 140 294 7.6 28 0.62 122 103 38 134 56.2 8.3 4900 211000 20 1 3.28 66
87 17230819 2 53 F 23.45 129 243 8 26 0.75 64 104 48 206 20 9.4 4800 220000 21 0 4.67 62
88 21822062 2 45 M 26.39 138 216 7.1 18 0.8 94 108 48 168 25 9.6 7400 275000 32 0 4.21 67
89 13894911 2 52 M 26.12 134 264 7.6 28 0.92 76 88 44 170 25 12.8 7600 328000 45 0 5.6 62
90 21574188 2 48 M 26.25 178 210 7.6 36 0.8 130 117 42 198 22 12.2 7400 202000 24 1 12.6 72
91 13502105 2 50 M 27.39 131 230 7.45 24 0.68 110 100 48 180 22 13.1 7600 310000 18 0 8.88 71
92 15751154 2 35 M 28.3 145 251 7.81 22.1 0.75 110 91 46 180 17 14.3 7600 323000 40 1 4.55 61
93 14525119 2 50 F 26.92 140 299 7.5 31 0.8 118 89 41 170 17 10.3 6400 210000 34 0 6.89 59
94 14398572 2 41 F 27.71 134 497 8.91 23 0.64 104.5 110 48 171 21 11.3 7800 156000 45 0 11.4 60
142
95 15759898 2 48 M 26.67 176 211 7.01 15.5 0.64 121 110 47 200 23 12.9 5600 240000 32 0 5.88 61
96 1277314 2 38 F 36.65 156 287 8.1 37 0.44 134 98 45 210 20 9.8 8000 267000 37 2 13.7 62
97 22216735 2 44 M 26.39 140 240 7.2 30 0.9 136 98 56 181 19 14.1 5900 256000 28 0 8.8 66
98 16809812 2 58 F 26.02 130 395 8.9 18 0.5 83 90 48 211 18 12.7 7000 298000 16 1 14.98 62
99 23045720 2 39 F 25.6 134 390 7.7 23 0.8 139 126 47 220 27 11.9 6800 254000 19 0 11.52 61
100 11719288 2 44 F 24.73 194 225 8.1 30 0.55 126 140 43 210 17.6 11.8 7800 234000 40 0 7.89 69
101 152262803 2 56 M 28.04 160 189 7.3 23 0.58 114 90 58 174 17 15.1 8200 320000 30 0 8.6 70
102 152262803 2 48 F 31.2 132 230 6.9 25.11 0.6 131 88 50 182 28 11.5 8100 280000 10 0 12.67 77
103 15893981 2 47 F 28.95 160 217 7.1 28.9 0.8 117 83 49 203 25 13.5 5600 264000 18 0 6.7 98
104 22346647 2 48 M 23.83 159 195 7.6 40 0.61 107 90 46 188 30 14.9 5800 258000 26 0 18.99 72
105 15618182 2 63 F 19.84 158 276 8.9 36 0.54 88 130 38 190 26 12.4 7300 278000 16 0 8.48 81
106 22760164 2 44 M 23.55 166 260 8.01 32 0.7 70 150 41 176 56 9.6 9000 239000 23 0 8.01 71
107 16268641 2 52 F 23.66 126 210 7.4 12 0.64 108 93 37 188 27 10 7100 376000 38 0 8.04 65
108 12836218 2 64 M 24.12 155 238 8.4 18 0.6 104 110 35 181 27 14 8000 265000 19 0 8.4 69
109 20659906 2 52 F 32 126 215 6.8 15 0.9 79 98 45 176 25 11.4 4800 253000 21 2 7.8 71
110 20287401 2 62 M 30.46 147 182 6.7 9.8 0.5 119 87 41 180 33 15 6400 310000 17 0 6.8 72
111 20050082 2 45 F 26.57 162 300 8.4 25.8 0.8 79 154 59 174 25 12.3 6100 159000 26 0 3.2 77
112 17019822 2 64 M 26.66 210 205 7.32 15.6 0.55 115 90 46 156 17 9.4 6700 237000 26 0 16.8 78
113 11748724 2 29 F 17.96 132 373 9.3 28 0.58 120 87 48 221 12 8.4 6100 186000 16 1 11.8 72
114 21548941 2 65 M 27.04 210 211 7.9 31 0.76 66 99 50 198 24.6 11 6500 345000 10 0 8.4 69
115 13491258 2 48 F 31.64 146 328 8.7 29.5 0.9 112 145 49 210 35 13.5 7400 310000 22 0 2 101
116 14754383 2 50 M 27.68 162 187 6.9 30 0.62 68.4 110 45 220 33 9.2 8500 284000 9 0 8 95
117 20039204 2 60 F 27.23 128 300 12.57 18 0.56 139 105 52 172 32 11.2 7400 247000 42 1 8.2 82
118 21137361 2 66 M 28.06 146 215 6.5 20 0.43 98 115 54 150 28 11.4 5400 238000 30 1 8.48 72
119 22123711 2 38 F 23.87 130 373 10.61 13.7 0.56 118 78 35 190 22 12.2 5600 274000 28 1 6.89 69
120 15695276 2 45 F 28.06 148 292 7.7 21.3 0.51 178 134 55 150 32 15.7 8100 239000 18 2 18.16 71
121 21425927 2 48 M 27.37 142 259 6.6 21.9 0.42 137 110 38 198 24 12.2 5400 243000 23 1 9.85 72
122 17741710 2 50 F 25.63 153 238 7 14.5 0.67 116 110 47 178 26 15.6 7800 222000 10 1 6.91 77
123 2538017 2 65 M 29.77 246 240 7.3 28 0.48 110 95 49 165 19 10.76 7100 244000 20 0 3.66 86
124 20117052 2 46 M 24.65 131 343 8.6 22 0.71 98 94 45 189 18 12 7200 277000 29 0 2.8 88
125 21950232 2 44 F 25.91 145 254 7 14 0.61 62 105 41 168 31 11.2 6700 206000 18 2 5.18 90
126 17037422 2 36 F 27.4 130 266 7.1 30 0.76 88 96 48 188 26 13 5900 208000 24 0 7.89 101
127 17230198 2 29 M 21.08 262 320 7.2 14 0.67 121 140 44 210 18 11.2 9400 310000 22 1 5.45 98
128 21822620 2 38 F 21.96 219 302 8.4 18.6 0.8 98 100 52 184 21 12.2 6700 283000 34 0 7.89 87
143
129 13894918 2 50 F 26.4 127 260 7.4 23.9 0.79 110 94 54 188.8 20 12 8900 243000 6 0 10.87 82
130 21541788 2 39 M 26.56 132 328 7.8 20.7 0.69 134 115 34 178 22 10.2 6600 341000 20 0 6.78 81
131 13984912 2 60 M 26.72 142 336 7.98 28 0.68 154 90 54 168 21 11.4 7800 210000 22 2 12.4 82
132 21578144 2 52 F 19.13 117 300 8.01 32 0.5 164 86 38 161 17 15.8 8200 247000 18 0 9.67 77
133 13502150 2 31 F 20.79 137 324 7.5 18 0.77 220 185 48 202 18 10.8 9300 310000 28 1 13.87 72
134 16480102 2 36 M 29.43 186 240 8.1 32 0.75 213 139 48 208 25 14.3 9900 267000 9 0 7.8 77
135 20440636 2 50 F 18.59 140 208 8.5 28 0.7 219 174 44 211.8 18.9 12.1 6700 298000 16 0 5.67 82
136 21060520 2 47 F 25.31 117 290 8.6 26 0.45 165 144 42 210 18.8 11.3 7100 345000 11 0 7.45 81
137 14525129 2 39 M 26.56 152 292 8.5 18 0.48 134 204 48 180 25.6 15.4 6300 234000 31 0 10.11 84
138 14397582 2 45 M 28.67 117 259 7.1 28 0.62 174 134 51 185 22.4 12.4 5900 213000 19 0 4.13 89
139 24406363 2 51 M 29.24 132 238 6.9 36 0.54 187 140 43 194 26.7 10.3 8800 267000 12 0 11.56 66
140 15798984 2 38 M 29.06 187 240 6.7 32 0.48 198 86 34 174 27 14.4 7600 321000 15 0 3.99 62
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7400 210000 21 1 3.22 65
1
158024
07 1 45 F 25.53 130 210 7.1 20 0.76 54 84 52 118 15
11.20
% 6700 320000 47 0 6.8 60
2
132628
03 1 39 F 24.06 156 268 6.5 28 0.31 55 82 41 180 22 11 5400 320000 45 1 7.6 64
3
211696
35 1 50 M 29.54 134 261 7.3 40 0.38 128 109 50 188 31 12.2 6400 245000 53 0 5.2 67
4
154189
04 1 38 F 27.64 154 278 6.8 42 0.44 88 96 47 178 22 9.6 4900 265000 39 0 7.6 72
5
154609
18 1 29 M 27.6 160 230 8.3 20 0.58 114 104 50 192 21 12.8 5400 245000 45 0 3.7 88
6
195325
8 1 49 F 30.8 156 213 6.6 42 0.52 88 88 66 167 32 12.4 7000 265000 48 1 1.45 91
7
172206
54 1 46 F 26.06 134 234 6.4 38 0.54 112 93 48 222 42 12 6500 345000 21 0 6.5 46
8
136941
95 1 47 M 23.04 177 254 7.1 30 0.53 98 87 50 245 30 11 5300 330000 26 0 7.3 55
9
156713
77 1 56 F 22.53 142 175 7.6 34 0.74 94 107 43 190 26 12 6900 234000 32 0 1.4 72
10
118860
89 1 58 M 30.53 153 224 6.4 34 0.61 102 98 61 154 24 11.2 5200 245000 36 1 6.6 62
11
152461
33 1 65 F 33.98 176 245 6.4 46 0.54 96 86.5 49 172 47 12 5900 365000 27 0 2.24 55
12
177700
34 1 35 M 27.6 185 270 6.2 33 0.64 112 92.5 54 177 42 11 4900 360000 6 0 7.8 59
13
211370
46 1 56 F 28.88 129 267 6.9 34 0.71 108 118 48 182 36 10.2 8900 375000 24 1 5.6 74
14
128460
25 1 67 F 29.41 156 267 7.5 19 0.54 111
118.
8 42 164 38 12.7 5900 250000 17 0 1.48 72
15
146446
13 1 57 M 27.08 165 209 7.3 26 0.46 114
230.
6 43 176 32 12 6400 265600 16 1 5.67 66
16
122335
60 1 58 F 23.13 156 240 8.9 28 0.48 120 222 38 166 28 9.9 5400 260000 32 0 6.7 63
145
17
138900
74 1 54 M 31.15 151 198 8.2 32 0.76 108 123 45 165 27 9.8 9000 290000 90 0 5.64 103
18
119359
14 1 60 F 29.41 196 241 7.1 33 0.84 88 146 50 182 31 10.2 7300 254000 9 0 5.6 93
19
128171
86 1 54 F 29.4 154 209 8.2 34 0.47 92 99 44 184 42 11 6500 360000 23 0 8.6 88
20
216689
62 1 48 M 30.9 173 208 8 36 0.8 86 94 65 157 43 12 7900 350000 14 1 5.9 73
21
200267
78 1 54 F 21.3 180 265 7.9 32 0.8 88 87 44 177 20 9.8 5900 241000 19 1 3.22 72
22
216689
26 1 44 F 25.6 190 209 6.9 22 0.9 56.8 85 48.6 126 18 11 7200 294000 37 0 5.6 70
23
200268
77 1 38 M 30.08 101 209 6.5 18 0.61 116 79 40 166.8 16 10.9 6500 250000 24 0 7.6 72
24
125979
61 1 38 M 29.06 121 235 7.1 26 0.54 84 124 50 154 18 11.6 6400 254000 24 0 4.67 62
25
203933
76 1 50 F 32.4 122 201 6.9 30 0.86 110 94 48 148 21 11 7900 320000 35 2 8.98 65
26
216287
03 1 44 M 26.53 156 280 8 32 1.02 90 103 49 168 18 11 8900 360000 10 0 10 63
27
171512
41 1 47 F 34.9 124 209 7 34 0.59 106 92 65 208 16 13 5600 320000 25 0 6.98 62
28
166449
88 1 40 M 28.85 121 246 7.1 22 0.66 108 83 48 168 17 14 7500 250000 20 0 6.5 76
29
117211
049 1 49 M 29.8 126 198 7.2 24 0.56 115 125 56 192 25 11.6 7500 360000 27 0 6.82 60
30
132666
24 1 47 F 30.41 128 223 6.4 27 0.58 103 132 45 202 16 12.6 9000 350000 18 0 5.6 77
31
172110
49 1 29 M 29 166 309 7.2 36 0.65 97 88 67 196 17 12 7100 250000 29 0 8.4 82
32
136645
66 1 46 F 23.18 145 209 7.1 32 0.48 76 82 46 154 26 14 4500 320000 6 0 6.7 77
33
172110
49 1 47 M 32.9 145 260 7.2 38 0.62 79 87 50 168 23 13.6 6200 320000 19 0 7.8 62
34
132266
56 1 56 F 24.6 130 207 6.9 28 0.51 93 95 46 188 26 14.2 7500 300200 20 0 7.4 63
35
172110
49 1 43 M 25.83 124 194 6.2 32 0.68 88 122 44 186 24 14.4 11000 300000 18 1 6.5 62
36
144994
64 1 57 F 29.04 189 215 8.3 28 0.6 92 243 48 174 52 12 8000 273000 20 0 1.48 57
37
144314
45 1 52 M 29.8 178 267 7.2 22 0.7 80 104 46 149 26 13 9600 360000 9 0 2.24 66
146
38
207181
12 1 53 F 26.5 152 265 6.3 16 0.64 104 127 40 152 26 14.4 9500 312000 17 2 7.8 62
39
167989
01 1 45 F 30 130 192 7.1 34 0.72 95 118 52 163 22 11 7000 250000 11 0 3.56 98
40
160752
25 1 52 F 24.1 149 219 7.2 16 0.66 78 101 43 158 32 14 5400 275000 31 0 5.67 74
41
216391
57 1 48 M 28.39 138 215 6.9 32 0.64 83 156 63.4 164 24 12 7500 250000 19 0 6.6 76
42
208551
70 1 50 F 25.48 156 228 7.2 25 0.62 92 89 48 133 15 11.6 7000 310000 12 0 6.8 75
43
167989
01 1 35 M 25.9 130 200 6.9 30 0.62 72 86 52 127 15 12 7400 260000 10 0 7.47 66
44
160152
25 1 50 M 26.2 145 235 7.3 22 0.76 120 114 54 203 22.4 15 6300 350000 14 0 7.8 71
45
216391
57 1 41 M 30.1 126 206 6.9 22 0.92 97 159 53 189 32 12 6800 350000 13 0 7.4 62
46
208551
70 1 48 F 28.01 167 234 7 21 0.88 98 108 48 211 28 12 7200 250000 24 1 6.7 83
47
145980
0 1 38 M 24.57 127 232 7.4 36 0.39 81 112 55 197 27 12.6 8500 350000 22 0 8.4 85
48
128318
04 1 44 M 25.38 209 231 8.2 28 0.58 79 106 61 178 25 12 5200 332000 17 1 4.2 82
49
145958
00 1 58 F 26.83 123 207 6.9 20 0.73 101 77 41 132 18 11.4 8000 350000 20 0 4.4 88
50
128381
04 1 39 F 28.4 217 256 7.2 28 0.61 110 146 52 213 29 12 5200 322000 20 1 3.28 81
51
216654
78 1 44 M 27.9 166 208 7.1 23 0.56 108 99 46 122 22 8.8 4800 302000 21 0 4.67 85
52
143856
36 1 56 M 24.29 152 276 7.8 22 0.67 66 101 45 191 24 9 6400 250000 29 0 4.21 72
53
212837
78 1 48 F 31.5 123 203 6.9 24 0.56 92 97 47 151 18 10 7500 210000 39 0 5.6 67
54
166486
86 1 47 M 30.06 136 243 7.1 29 0.65 75 92 53 162.1 19 13 6800 260000 24 0 10.4 60
55
213092
76 1 48 F 33.4 126 208 7.2 32 0.72 112 115 45 182 26 12 7500 378000 18 0 8.88 67
56
205225
54 1 63 F 24.5 129 227 7.1 28 0.65 102 102 42 173 24 13.5 6400 260000 21 1 3.22 69
57
163178
57 1 29 F 34.8 134 205 7.1 22 0.79 58 87 59 116 19 11 7200 230000 34 0 6.88 59
58
205225
54 1 46 M 27.5 109 220 6.3 24 0.68 122 85 44.6 166.4 17 10.2 5900 210000 23 0 7.88 62
147
59
163178
57 1 47 F 27.65 121 245 7.2 26 0.82 89 124 54 146 18 11 7000 200000 26 0 4.67 71
60
176425
61 1 53 M 30.1 114 186 6.4 32 0.72 109 98 48.6 144 21 10.4 8500 250000 40 0 8.98 62
61
207581
11 1 43 F 27.08 123 243 7.5 36 0.76 93
103.
6 52 171 24 10.2 8000 214000 10 0 10.3 69
62
203190
47 1 57 M 24.8 129 209 6.3 37 0.6 106 96 66 212 23 13 5200 321000 20 0 6.98 70
63
205225
41 1 52 F 32.5 129 202 6.9 22 0.62 107 88 53 165 33 14.5 7000 250000 21 0 5.3 62
64
217870
11 1 53 M 24.86 120 209 6.9 20 0.56 118 145 58 188 24 10.3 8200 290000 30 0 5.6 89
65
206403
87 1 45 F 26.9 143 204 6.3 26 0.8 113 125 41.6 193 31 13.1 7500 301000 22 0 5.6 76
66
220089
12 1 56 M 27.4 136 237 7.2 40 0.63 104 87 67 183 24 11 8000 320000 24 0 8.3 70
67
206403
87 1 38 F 25.8 146 205 7.1 28 0.61 82 93 54 154 37 11.5 4800 312000 6 0 6.7 62
68
217870
11 1 45 M 27.8 127 210 7.1 42 0.65 78 79 55 172 15 12.5 8000 350000 20 0 7.2 63
69
206403
87 1 58 F 28.8 109 203 6.2 27 1.1 99 94 56 174 22 14.4 8700 300000 22 0 8.66 89
70
220089
12 1 51 M 29.1 147 199 6.5 22 1.02 102 119 49 182 19 14 7900 244010 18 0 6.5 81
71
217676
62 2 44 M 31 198 215 8.9 28 0.9 97 266 56 182 32 12 8500 450000 24 0 1.48 77
72
171300
38 2 38 M 26.3 120 206 7.1 18 0.84 85 103 45 160 31 13.7 9000 218000 9 0 2.24 83
73
111895
48 2 38 F 26.1 102 127 6.3 16 0.6 120 130 52 166 27 13.3 8900 262000 16 1 11.3 64
74
211377
19 2 50 F 28.5 130 192 7.2 32 0.8 105 119 65 172 18 11 7500 320000 11 0 3.56 68
75
155832
52 2 44 M 29.8 167 201 7.3 12 0.54 86 98 53 163 20 14 6000 164000 31 0 5.67 69
76
119898
62 2 47 F 26.1 138 205 7 32 0.81 93 166 72 174 16 12 7600 230000 19 0 8.64 63
77
171249
08 2 40 M 39.5 136 290 7.2 22 0.58 85 90 52 144 27 11 8000 191000 12 0 6.8 63
78
218590
96 2 49 F 25.3 123 198 6.9 16 0.56 78 83 57 132 25 10.5 8500 350000 19 0 7.47 62
79
218950
69 2 47 F 33 125 205 7.2 19 0.71 112 119 64 214 55 15 7800 318000 14 0 7.8 62
148
80
127391
85 2 29 F 21.9 126 196 6.9 27 0.56 105 167 62 197 17 12 7200 256000 13 0 8.99 61
81
113463
70 2 46 M 34.51 127 202 7.2 23 0.65 108 110 56 213 42 11.7 7000 216000 24 1 6.7 63
82
166486
86 2 47 M 24.61 126 220 7.8 32 0.54 87 113 59 216 15 12.8 7000 280000 22 0 8.4 73
83
168882
11 2 53 F 24.8 202 284 8.9 36 0.68 85 111 63 172 26 12.9 6000 250000 17 1 4.2 66
84
165957
26 2 43 F 29.41 102 244 6.9 22 0.55 99 78 54 132 28 11.2 8500 282000 24 1 4.4 63
85
212495
28 2 57 F 30.64 200 204 7.2 31 0.71 101 144 64 203 32 11.5 5200 211000 20 1 3.28 69
86
170372
24 2 52 M 25.77 149 284 7.1 32 0.66 108 99 44 127 46 8.6 5400 220000 21 0 4.67 65
87
172308
19 2 53 F 23.57 121 223 7.8 27 0.72 77 104 56 186 18 9.9 8700 260000 32 0 4.21 69
88
218220
62 2 45 M 26.9 143 206 6.9 26 0.79 88 108 57 149 23 10.1 6800 328000 34 0 5.6 68
89
138949
11 2 52 M 26.29 147 164 7.5 34 0.84 77 89 63 163 22 12 7500 202000 24 2 11 73
90
215741
88 2 48 M 27.5 156 207 7.4 38 0.9 109 114 54 174 19 12.4 8000 310000 18 0 6.7 72
91
135021
05 2 50 M 28.9 121 209 7.2 29 0.75 103 95 53 163 19 13 8700 323000 34 1 4.55 68
92
157511
54 2 35 M 29.3 154 293 7.1 24 0.8 97 90 51 167 18 14 6800 210000 34 0 5.3 63
93
145251
19 2 50 F 27.2 130 197 7.2 36 0.9 99 94 47 158 22 11 8500 210000 45 0 9.3 60
94
143985
72 2 41 F 26.61 124 297 7.7 28 0.6 92.4 103 53 166 17 12 9600 240000 32 1 5.88 63
95
157598
98 2 48 M 25.7 164 201 6.9 18 0.59
102.
6 112 55 186 18 13 8500 267000 34 2 11 66
96
127731
4 2 38 F 35.51 124 247 7.1 41 0.6 120 91 49 193 17 10 6500 256000 28 0 8.8 69
97
222167
35 2 44 M 27.92 129 203 6.9 38 1.3 114 96 63 114 16 14 7500 298000 16 0 10 68
98
168098
12 2 58 F 27.2 103 293 8.2 21 0.49 84 92 52 203 17 13 6900 254000 19 0 9 67
99
230457
20 2 39 F 25.6 154 203 7.5 22 1.02 122 117 49 213 26 12 8400 234000 40 0 7.89 72
100
117192
88 2 44 F 25.73 294 234 7.8 28 0.74 118 134 48 195 18 12 8600 230000 30 0 8.6 71
149
101
152262
803 2 56 M 28.04 109 191 7.2 22 0.63 106 93 47 166 16 14.6 8400 280000 10 0 11 79
102
152262
803 2 48 F 32.2 126 200 6.3 26 0.52 122 87 54 1169 25 12 5900 264000 18 0 6.7 101
103
158939
81 2 47 F 29.5 150 207 6.9 32 0.71 108 86 52 173 24 13 5900 258000 26 0 12 72
104
223466
47 2 48 M 24.3 144 191 7.2 42 0.56 105 92 48 159 28 14.2 5800 278000 16 0 6.8 78
105
156181
82 2 63 F 19.4 151 266 8.5 38 0.53 90 106 44 172 25 12 8500 239000 23 0 7.3 72
106
227601
64 2 44 M 23.53 154 189 7.8 30 0.66 77 136 47 166 44 9.4 7100 376000 34 0 6.2 76
107
162686
41 2 52 F 24.61 121 218 7.2 14 0.58 101 91 46 174 22 11 8000 265000 19 0 8.4 71
108
128362
18 2 64 M 25.2 109 278 8.2 22 0.65 95 106 42 173 21 13.8 5400 253000 21 2 6.3 77
109
206599
06 2 52 F 32.67 121 209 6.4 18 0.88 84 92 54 158 24 11.5 9000 310000 17 0 6.8 76
110
202874
01 2 62 M 31.6 129 178 6.5 18 0.54 107 88 48 168 30 14.4 6500 159000 26 0 3.2 79
111
200500
82 2 45 F 27.71 155 260 8.4 27 0.78 83.5 144 68 165 20 12.8 7200 320000 26 0 11 81
112
170198
22 2 64 M 27.61 202 219 7.32 17 0.6 108 92 53.4 144 26 9.8 6800 186000 16 0 8.9 75
113
117487
24 2 29 F 17.6 122 333 9.3 26 0.4
112.
8 90 54 205 12 8.8 6400 320000 10 0 8.4 71
114
215489
41 2 65 M 28.4 198 231 7.9 30 0.8 73 93 61 178 22 11.4 7500 310000 22 0 2 109
115
134912
58 2 48 F 30.4 176 239 8.3 28 1.1 110 137 56 194 32 13.2 8900 284000 9 0 8 99
116
147543
83 2 50 M 26.81 126 178 6.2 27 0.49 72 102 53 188 28 9.4 7800 247000 23 1 8.2 89
117
200392
04 2 60 F 26.3 128 290 11 25 0.47 124 99 58 158 27 11 5800 238000 30 2 6.34 76
118
211373
61 2 66 M 28.06 106 195 6.5 26 0.7 100 106 64 143 23 11.2 6000 274000 22 1 6.89 72
119
221237
11 2 38 F 21.7 103 273 10 15 0.82 111 87 48 168 18 12 7800 239000 18 2 11 72
120
156952
76 2 45 F 27.6 108 192 7.5 22 0.61
160.
6 127 67 135 27 15 9000 243000 23 1 9.85 75
121
214259
27 2 48 M 27.4 129 239 6.5 27 0.38 130 106 46 175 22 12.1 6800 222000 10 0 5.5 79
150
122
177417
10 2 50 F 26.32 143 148 6.9 18 0.72 112 97 45 157 24 15.1 9000 244000 20 0 3.66 89
123
253801
7 2 65 M 28.7 240 270 7.2 32 0.37 107 99 52 164 17 10.4 8000 277000 29 0 2.8 79
124
201170
52 2 46 M 25.5 129 245 8.5 28 0.56 99 88.6 47 174 16 12.4 7200 206000 18 2 5.18 92
125
219502
32 2 44 F 25.91 123 208 6 18 0.68 72 98 46 156 27 13 6800 208000 24 0 6.76 108
126
170374
22 2 36 F 28.4 101 226 7 34 0.66 86 102 56 173 23 12.7 9400 310000 22 1 5.45 99
127
172301
98 2 29 M 22.8 221 226 6.9 18 0.65 113 140 55 188 19 11.6 6700 283000 33 0 7.89 91
128
218226
20 2 38 F 21.6 193 222 7.5 22 0.74 95 103 64 166 16 12 6900 243000 6 0 7.9 85
129
138949
18 2 50 F 27.44 121 240 6.9 27 0.65 101 97 58 171 21 11.8 9000 341000 20 0 6.78 87
130
215417
88 2 39 M 25.6 142 228 7.4 25 0.62 123 106 42 156 19 11 7900 210000 22 2 12.4 86
131
139849
12 2 60 M 27.2 122 360 7.5 32 0.54 148 95 55 158 18 11.7 8500 247000 18 0 6.3 81
132
215781
44 2 52 F 19.3 154 291 7.9 43 0.42 157 88 43 152 21 15.2 8000 320000 22 0 11 81
133
135021
50 2 31 F 21.9 117 224 7.4 26 0.65 170 175 53 187 19 11 8600 267000 9 0 7.8 81
134
164801
02 2 36 M 29.9 156 202 7.4 44 0.66 192 128 65 178 22 14 6700 298000 16 0 5.67 88
135
204406
36 2 50 F 18.59 120 198 8.2 32 0.64 181 167 66 192 17.4 12 8000 345000 11 0 7.45 84
136
210605
20 2 47 F 25.31 117 290 8.2 28 0.32 155 138 44 182 17.4 11 7300 234000 22 0 9.4 87
137
145251
29 2 39 M 26.56 152 292 8.2 22 0.63 112 189 52 168 22.4 15.5 6000 260000 19 0 4.13 91
138
143975
82 2 45 M 28.67 117 259 6.9 32 0.54 158 127 55 174 21.6 12 9000 267000 12 0 8.9 70
139
244063
63 2 51 M 29.24 132 238 6.5 34 0.65 162 131 46 166 24.6 10.1 8900 321000 15 1 2.4 69
140
157989
84 2 38 M 29.06 187 240 6.4 41 0.17 176 87 44 162 23 14.6 9100 310000 19 0 3.3 70
